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Herpes simplex virus type 1 (HSV-1) latency in sensory ganglia such as trigeminal 
ganglia (TG) is associated with a persistent immune infiltrate that includes effector memory 
CD8+ T cells that can influence HSV-1 reactivation.  In C57BL/6 mice, HSV-1 induces a highly 
skewed CD8+ T cell repertoire, in which half of CD8+ T cells (gB-CD8s) recognize a single 
epitope on glycoprotein B (gB498-505), while the remainder (non-gB-CD8s) recognize, in varying 
proportions, 19 subdominant epitopes on 12 viral proteins.  The gB-CD8s remain functional in 
TG throughout latency, while non-gB-CD8s exhibit varying degrees of functional compromise. 
To understand how dominance hierarchies relate to CD8+ T cell function during latency, we 
characterized the TG-associated CD8+ T cells following corneal infection with a recombinant 
HSV-1 lacking the immunodominant gB498-505 epitope (S1L). Instead, there was a general 
increase of non-gB-CD8s with specific subdominant epitopes arising to codominance. In a latent 
S1L infection, non-gB-CD8s in the TG showed a hierarchy targeting different epitopes at latency 
compared to acute times, and these cells retained an increased functionality at latency. These 
data indicate that loss of the immunodominant gB498-505 epitope alters the dominance hierarchy 
and reduces functional compromise of CD8+ T cells specific for subdominant HSV-1 epitopes 
during viral latency.  To address how expression from the viral genome influences this CD8+ T 
hierarchy, we developed recombinant in the S1L background that expressed ectopic gB498-505 
copies under the influence of several candidate promoters with different expression kinetics.  
Ectopic epitope expression from the early or strong promoters restored full gB-CD8 
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 v 
immunodominance.  However, epitope expression from candidate viral true late gene promoters 
resulted in delayed or severely reduced priming efficiency of gB-CD8s, with indications of low 
levels of late epitope expression in the TG sufficient to retain primed gB-CD8s.  Epitope 
expression from latently active promoters could efficiently attract and expand gB-CD8s in the 
TG.  These data indicate that viral antigen expression during latency will influence the CD8+ T 
cell hierarchy that is monitoring a latently infected TG.   
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1.0  INTRODUCTION 
The word ‘herpes’ has been used in medicine for at least 2,600 years, dating back to early 
descriptions of skin diseases that likely included Herpes Simplex Virus (HSV) lesions, Herpes 
Zoster rashes, and other similar skin maladies[1]. As one might expect from a virus with such 
ancient recognition, Herpesviridae is a ubiquitous and wide-ranging virus family. This family 
also contains a myriad of mollusk, bird, reptile, and mammal hosts throughout the world. In fact, 
when investigated closely, most animal species harbor at least one herpesvirus, with nearly 200 
identified Herpesviridae family members to date, with a large majority unlooked for, and likely 
undiscovered thus far[2, 3]. In general, most herpesviruses are highly adapted to one or few host 
species, and severe symptoms often only occur in the very young or immunocompromised. 
Given the long coevolution of herpesviruses with life on this planet, it is perhaps unsurprising 
that they have evolved a vast array of complex and varied mechanisms to survive, hide, and 
spread within their host populations. 
1.1 HUMAN HERPESVIRUSES  
There are nine currently identified human herpesviruses, that are classified into the 
subfamilies of alpha-, beta-, or gammaherpesvirinae[2, 4]. These viruses all share similar 
structural elements and the ability to establish latent infections in humans. Latency within the 
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broad context of human herpesviruses can be defined as an extended period in which no 
infectious viral particles are made, yet viral DNA is retained within the host, and the possibility 
of reactivating to produce infectious virus is retained. Alphaherpesvirus members include Herpes 
simplex virus type 1 (HSV-1) and 2 (HSV-2), and Varicella-zoster virus (VZV), and typically 
have a rapid primary lytic cycle that quickly establishes latency within sensory neurons.  
Betaherpesvirus members include Cytomegalovirus (CMV) and Roseolovirus (including HHV-
6A, HHV-6B, and HHV-7) which commonly replicate at a slower rate and establish latency 
within monocyte-lineage cells.  CMV is one of the leading causes of congenital birth defects[5]. 
Gammaherpesviruses latently infect immune cells such as lymphocytes and include Epstein-Barr 
virus (EBV) and Kaposi’s Sarcoma associated herpesvirus (KSHV). Both EBV and KSHV are 
also of note due to their oncogenic potential, with EBV linked to lymphomas and 
nasopharyngeal carcinomas, and KSHV causing Kaposi's sarcoma, a cancer commonly occurring 
in AIDS patients[6]. 
1.2 HSV-1 EPIDEMIOLOGYAND DISEASE 
Many humans encounter HSV early in life, with asymptomatic primary disease affecting 
one or more mucosal regions that lead to latent infections within innervating sensory and 
sympathetic ganglia [7, 8]. Infection rates vary greatly by geographic region, however by the age 
of 15, more than 40% of humans are seropositive for HSV-1, and by the age of 40, over 80% of 
people have encountered HSV-1 [9-11]; Seroprevalance is as high as 98% in some regions, and 
in general this virus is extremely ubiquitous within the adult population worldwide[11]. Most 
seropositive individuals never experience any outward pathologies associated with reactivation 
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events, although asymptomatic shedding of infectious virus may be frequent[12]. Additionally, a 
fraction of those infected will reactivate with symptoms ranging from minor, such as (herpes 
labialis) cold sores, to major, such as herpetic whitlow, to life-threatening, such as herpes 
simplex encephalitis (HSE) [10]. Though HSE is rare (about four cases per million people per 
year), it is a leading cause of fatal viral encephalitis in neonates[13]. Another major consequence 
of HSV-1 reactivation is Herpes Stromal Keratitis (HSK), a consequence of repeated HSV 
reactivation events that cause a scarring and progressive loss of clarity of the cornea. HSK is a 
leading cause of infectious blindness in adults in western societies, with corneal transplants being 
the only current treatment for restoring vision to opaque corneas[14, 15]. 
1.3 HSV-1 STRUCTURE AND GENOME ORGANIZATION 
Characteristic to all herpesviruses are four highly conserved components of the viral 
particle. These include 1) The DNA core contains the dsDNA viral genome, which in HSV-1 is 
about 152,000 base pairs in size and encodes over 80 viral genes; 2) The viral capsid, which 
consists of an icosahedron composed of at least eight virally-encoded proteins; 3) a tegument 
layer, which is amorphous and contains at least 23 viral proteins, an unknown number of host 
proteins, and is instrumental in assembly, egress, and making newly infected host cells 
permissive to viral infection, with functions including capsid transport, immune evasion, and 
transcriptional regulation; and 4) the envelope, a lipoprotein layer studded with at least 13 viral 
glycoproteins vital for binding and entry, which also likely contains several host proteins[16]. 
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Figure 1. HSV-1 virion structure  
HSV-1 consists of an amorphous enveloped particle that is approximately 150-250nm in size, and which 
contains a proteinaceous tegument composed of mostly viral and some host proteins. Of note, included 
within the tegument is the viral protein VP16, which transactivates viral immediate early (α) gene 
expression. The tetrahedral nucleocapsid (which consists of 162 capsomers) contains a single copy of viral 
DNA consisting of about 152kb. Studded on the outside of the envelope are the viral proteins used for viral 
attachment and entry: notably, glycoproteins gB, gC, gD, and the complex gH/gL. Image created in 
CorelDRAW x7.  
  
 
The HSV-1 genome is encoded in linear dsDNA which circularizes to form an episome 
upon entry into the nucleus, by use of the homologous short “a” sequences located at either end 
of the genome[17, 18]. Other notable features of the HSV genome include two repeat regions 
within the genome— with the ~9kbp long repeat being especially important and containing 
several immediate early genes and the LAT locus, and the 6.6kb short repeat region containing 
ICP4, the major viral transactivator[19]. There are also two unique coding regions—the 108kb 
unique long region (UL), which encodes many important glycoproteins, structural and tegument 
proteins, and proteins involved in viral DNA replication, and the 13kb unique short region (US), 
which encodes an important viral kinase and glycoproteins[19]. 
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1.4 HSV-1 LIFE CYCLE 
1.4.1 Viral entry  
HSV-1 binds to cellular surfaces via interactions between viral glycoproteins and cellular 
surface receptors. The first interactions are generally with glycoprotein B and C (gB and gC) 
interacting with heparan sulfate chains, which are a class of glycosaminoglycan found on the 
surface of the vast majority of mammalian cells[20-22]. Though these initial binding interactions 
are very advantageous to the virus in the wild, in some experimental models, these heparan 
sulfate interactions can be dispensable for viral replication. Indeed, gC binding to heparin sulfate 
has been shown to be vital for infecting apical surfaces in intact skin or ocular surfaces, but is 
completely dispensable in models where the initial infected region has a disrupted epithelial 
layer which exposes the basal layer[23, 24]. 
After initial interactions mediating a close association between the viral particle and the 
target cell, secondary specific interactions are engaged. Viral glycoprotein D (gD), along with 
gB, bind to one of at least three major identified cellular surface receptors, depending on the cell 
type and context of infection. Herpesvirus entry mediator (HVEM), nectin-1 and nectin-2, as 
well as specific sites within heparan sulfate (characterized by 3-O-sulfated residues) are the 
identified receptors that HSV-1 uses to gain entry within cells[25]. The actual fusion event is 
mediated by a protein complex consisting of gB, along with a heterodimer formed by gH-gL. 
The current model is that tight gD anchoring to specific cellular receptors promote a 
conformational change within the gB/gH-gL complex, after which this complex undergoes a 
radical conformational change and pierces the target cell membrane, initiating the viral 
envelope/cellular membrane fusion process[26, 27]. These entry and membrane fusion events 
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occur at either the cellular surface, or within endosomal compartments, again depending on the 
cell type and context of infection[28, 29]. 
HSV-1 also has a wide variety of putative minor binding and entry receptors that are not 
discussed here. HSV-1 has been identified as capable of infecting most human cell types in vitro, 
and the ability to bind and enter many animal cell types leads to the broad host range mentioned 
previously[30]. This broad range of receptors and entry methods in part explains HSV-1’s ability 
to infect many disparate hosts, and is one reason that this virus is ideally suited for use in animal 
models. 
 
1.4.2 Lytic infection cycle and gene expression  
After viral envelope fusion and entry within the cell, the capsid containing the viral 
genome is transported to the nucleus via microtubules and viral tegument protein interactions 
with host dynein[31, 32]. Once docked at the nuclear pore complex, the viral DNA enters the 
nucleus through the pore. The viral tegument contains VP16 (UL48), which enters the nucleus 
along with host cell factor (HCF) and, once in the nucleus interacts with another host protein, 
Oct-1, to form a complex that initiates transcription of the viral immediate early (α) genes[33-
36]. At this time, the tegument has also delivered other viral products that acclimate the cellular 
environment for viral replication. Among these are the virion host shutoff (VHS, UL41), which 
contains RNase activity and is responsible for degrading host messenger RNA to counteract viral 
innate immune defenses[37, 38]. Also contained within the tegument are the viral 
serine/threonine kinases encoded by US3 and UL13, which are highly active and promiscuous 
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viral kinases that regulate a large range of host cellular functions that include regulation of 
pro/anti-apoptotic proteins and inhibition of type-1 interferon responses[41-43]. 
Initiation of viral transcription by the VP16 complex results in the production of viral 
immediate early (α) genes – including ICP0, ICP4, ICP22, ICP27, and ICP47[19]. The first four 
of these genes are involved in promoting and regulating the transcription and expression of the 
next wave of genes, the early (β) genes. In particular, ICP0 is an E3 ubiquitin ligase that 
promotes the degradation of many cellular targets, including promyelocytic leukemia (PML) and 
SP100 [44, 45]. ICP0 also can transactivate cellular genes promiscuously in part by binding 
CoREST and dissociating histone deacetylases (HDACs)[46]. ICP4 is the major viral 
transcription factor required for virtually all viral β and late (γ) gene transcription[19, 47, 48]. 
ICP47 has a different role – this viral gene encodes a protein that selectively binds to and inhibits 
human TAP1/TAP2 and blocks the transport of viral peptides into the endoplasmic reticulum 
where they would be subsequently presented at the cell surface by MHC-I[49, 50]. This has the 
net effect of hiding presented viral peptides from CD8+ T cell detection. 
The β gene products coordinate to replicate viral DNA and alter the cellular environment 
further to promote γ gene expression[19]. γ genes are divided into two categories, γ1 genes are 
referred to as “leaky late” genes, and the transcription of these genes are begun concordantly 
with β gene products, but only at low levels. After the onset of viral DNA replication, these 
genes are transcribed and make proteins at much higher levels. γ2 genes, or “true late” genes, are 
only made in any measurable quantity after viral DNA replication has already begun, at a very 
late stage of viral replication[19, 51, 52]. Taken as a group, the γ genes are the largest group of 
viral proteins, and encode many tegument, glycoprotein, and capsid proteins that make up the 
bulk of the structural proteins in the viral particle.  
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In cell culture models of HSV infections, such as in Vero cells (an African green-monkey 
kidney cell line), we can measure the differences in these kinetic classes of genes experimentally 
by inhibiting viral transcription, translation, or DNA replication at key points and measuring 
subsequent viral RNA or protein expression. We also can determine that in general, α gene 
expression peaks at 2-4 hours post infection (hpi), β gene expression peaks around 4-8 hpi, and γ 
genes vary more widely, with peak expression times at 8-12 hpi (depending on multiplicity of 
infection).  
Peak expression of viral late gene products correlates with the completion viral DNA 
replication and subsequent packaging into completed viral capsids within infected cell nuclei. 
The now completed capsids containing viral DNA pass through the perinuclear space, where 
they briefly are enveloped by the inner nuclear membrane, before de-envelopment upon fusion 
with the outer nuclear membrane and trafficking into the cytoplasm[19, 53]. Here, the viral 
capsids undergo secondary envelopment (with lipid membranes containing viral glycoproteins) 
and are transported to the cellular surface via exocytotic vesicles, and the infectious particles are 
subsequently released[53]. In general, cellular permissiveness for lytic viral infection results in 
the host cellular lysis and death.  
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Figure 2. HSV-1 lytic replication and gene expression 
(1) Initial attachment and entry mediated by viral glycoproteins, including gB, gD, and gH/gL. (2) Viral 
envelope fusion can occur at either the surface, or by endosomal escape within the cytosol. In both 
scenarios the viral capsid and tegument proteins are released into the host cytoplasm. (3) The viral 
nucleocapsid traffics inwards via microtubules, docks at the nuclear pore complex and viral DNA is 
released into the nucleus, whereupon it circularizes. (4) The tegument protein VP16 traffics into the nucleus 
with host transcription factors and turns on α gene expression, including the major viral transcription factor 
ICP4. Peak α gene expression occurs 2-4 hpi. ICP4-mediated expression of β genes peaks by 4-8 hours post 
infection, with low levels of γ1 genes also turned on at this time. After viral DNA replication commences, 
γ1 genes are maximally expressed and γ2 genes begin expressing, with these late genes peaking around 8-
12 hpi. (5) Viral DNA is packaged into capsids within the nucleus. Egress from the nucleus involves a 
temporary envelopment as the capsid traverses the nuclear membrane. (6) In the Golgi the virus obtains its 
tegument and becomes doubly enveloped. Fusion of the outer envelope at the cellular membrane releases 
an enveloped and fully infectious virion from the cell, ready to begin the infectious cycle again. Image 
created in CorelDRAW x7. 
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1.4.3 Latency 
The previous section described the lytic cycle of HSV-1, which is generally carried out at 
the surface cells of the host, and mainly includes mucosal epithelial cells and the surrounding 
tissues. Sensory neurons innervate these primary infection sites in large numbers to provide fine 
sensation to the host’s lips, eyes, and other mucosal areas. During the primary infection, the virus 
ultimately gains access to the axonal termini of these neurons, and is carried along microtubules 
to the nucleus, where a “decision” of sorts is made. Once the viral DNA is within the nucleus of 
sensory neurons, either a) the nuclear environment will be permissive to viral transcription 
mediated by VP16-initiation of α genes, and lytic viral replication will commence or b) the viral 
DNA in the nucleus is not accompanied by a functional VP16 complex (which may not have 
transported down the axon with the viral capsid) and becomes packaged into heterochromatin, 
with silencing of most viral transcription[54, 55]. This latter outcome is defined as viral latency. 
As the course of acute viral infection at the surface is controlled by a combination of innate and 
adaptive immune responses, most viral genomes in the sensory ganglia have entered a latent 
state. Accompanying viral latency is transcription of one large region on the viral DNA, referred 
to as the latency associated transcript (LAT), which is surrounded by chromatin insulating 
elements and ultimately results in large detectable amounts of a stable intron. This RNA encodes 
no protein, yet many putative functions have been ascribed to it, including protection of neurons 
from apoptotic cell death, regulation of heterochromatin and latency, and silencing viral genes to 
promote the latent state [56-60]. LAT accumulates in many latently infected sensory neurons 
both in humans and in animal models of latency.  
  11 
 
Figure 3. HSV-1 latency 
(1) HSV-1 infects mucosal epithelial cells and undergoes lytic viral replication and spread. (2) The virus 
gains access to the axonal termini from sensory neurons, whereupon the virus binds, and releases a capsid 
into the axon. Of note, most viral tegument proteins become separated from the capsid at this point, 
including VP16, the viral α gene transactivator. (3) The viral capsid traffics in a retrograde fashion along 
microtubules via the motor protein dynein, which delivers the capsid to the neuronal cell body. (4) once 
within the cell body, viral DNA is released into the nucleus. (5) In the absence of tegument proteins to 
provide an environment conducive to viral gene transcription, the genome quickly becomes packaged 
within heterochromatin and begins the latent phase of infection. Viral LAT RNAs are the only transcripts 
abundantly produced during this time. (6) There is an extremely low and sporadic amount of leaky viral 
gene expression during latency, which is unregulated and includes α, β, and γ viral genes. This gene 
expression is not easily detectable by traditional methods, and during latency does not result in detectable 
infectious virus. (7) Accompanying viral latency is an HSV-specific T cell infiltrate into infected ganglia, 
which are capable of monitoring and possibly preventing potential reactivation events. Image created in 
CorelDRAW x7. 
 
1.4.4 Reactivation 
Latent viral genomes are maintained in this state for the life of the host, except for brief 
bouts of lytic viral replication cycles defined as ‘reactivation’. The events preceding viral 
reactivation are multifactorial and complex, but have begun to come to light in recent years. 
While latency has in the past been defined by the absence of viral protein expression, it has 
begun to be widely accepted that there is a sporadic “leaking” of viral proteins arising from 
  12 
latently infected ganglia, which is termed “phase 1” or “animation”[61]. The evidence for this is 
multifactorial and quite convincing when taken as a whole: 1) several in vitro latency models 
show low levels of uncoordinated RNA transcription preceding true reactivation events[62-65]. 
2) Single cell PCR of latently infected dorsal root ganglia (DRG) consistently detects viral 
transcripts that represent many lytic viral genes[66]. 3) Floxed-reporter mice latently infected 
with HSV that express CRE from lytic promoters show cumulatively increasing numbers of 
CRE-switched neurons over long term studies, indicating low levels of ongoing viral promoter 
activity from lytic promoters throughout latency[67]. 4) Viral-specific CD8+ T cells show 
consistent signs of recently encountering viral antigen within latently infected ganglia[68]. Taken 
together, these data suggest a low-level and ongoing amount of phase 1 viral protein detection 
that is not detectable by traditional methods (i.e. qPCR, western blotting). Furthermore, the 
transcripts that are detected do not follow the classical α-β-γ gene cascade that is observed in 
lytic replication cycles[62]. The model that has emerged tells us that this phase 1 expression 
must reach a certain threshold – enough to make VP16 in amounts capable of transactivating 
viral α gene expression and begin the lytic cascade. Many factors affect the host transcriptional 
program and the state of chromatin, and hence the amount of phase 1 viral gene expression. 
Reduced levels of nerve growth factor, increased stress (brought on by UV-light, physical 
distress, or other means), reduced immune function, or chemical targeting of histone modifying 
enzymes all perturb this balance and can result in increased latent gene expression[59, 69, 70]. 
This can eventually result in “phase 2” of reactivation, where a threshold of viral transactivator 
expression is reached, and lytic viral replication proceeds[61]. 
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Figure 4. Reactivation from neuronal latency 
(1) In the face of waning T cell functionality, and in combination with increased stress or other conditions 
that result in subsequent chromatin changes, viral lytic gene expression can begin to ramp up during 
latency. (2) Sporadic phase 1 viral gene expression leads to production of VP16, which once a certain 
threshold is realized, can activate viral α gene transcription in some cases. (3) The commencement of α 
protein synthesis begins a cascade, which releases viral genomes from heterochromatin completely, and 
begins a classical α-β-γ lytic cascade. (4) Lytic viral replication cycle results in production of viral capsids 
containing DNA. (5) It is controversial whether capsids obtain an envelope within the cell body, or whether 
the capsid and tegument/envelope traffic separately and form infectious particles at axonal tips. (6) There is 
evidence that both occur, and regardless of the anterograde transport method, infectious HSV-1 is delivered 
to the periphery- whereupon it obtains access to mucosal epithelial cells and causes subsequent disease. 
Image created in CorelDRAW x7. 
1.5 MOUSE MODEL OF HSV INFECTION AND LATENCY 
The natural hosts for herpes simplex virus are humans, but both HSV-1 and HSV-2 are 
capable of undergoing lytic replication and establishing latency in many mammalian species 
under experimental conditions. There are several widely-used experimental animal models of 
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HSV infection, including the rabbit, which reactivates frequently and is an excellent model for 
therapies to block viral shedding; the guinea pig, which closely mimics genital HSV-2 infection 
and disease; and the mouse[71-75]. Mice infected with HSV-1 are ideally suited for studying 
viral latency and the accompanying immune response. The latent state and immune responses to 
both primary and latent infections have been widely characterized in this model, and additionally 
there exist a myriad of immunological tools available for mouse models. In mice, latent 
infections are established readily, and indeed reactivation in mice is difficult for a number of 
reasons, which include inefficient binding of VP16 to mouse Oct-1[76]. Reactivation of mouse 
models is possible by 1) UV-irradiation, 2) physical stress or social discomfort, or 3) histone 
modifying chemicals[59]. Ex vivo reactivation of latently infected ganglia is also possible, which 
will be discussed later. 
Mouse models can reproduce human diseases closely, including the blinding Herpes 
Stromal Keratitis (HSK) in ocular infection models, skin disease in flank infection models, and 
encephalitis by various infection models. In the following studies, we employ an ocular HSV 
infection model of C57BL/6 (B6) mice, which establishes a latent infection within the trigeminal 
ganglia (TG). The initial corneal infection is controlled primarily by innate immunity, followed 
by a subsequent adaptive response that is vital for controlling further viral progression. In 
particular, the latent infection is accompanied by a protective CD8+ T cell response that is highly 
virus-specific, and is maintained in latently infected TG for the life of the animal[77, 78]. 
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1.6 HSV-1 IMMUNOLOGY 
1.6.1 Intrinsic and innate immune response to HSV-1 
Primary infected cells include mainly mucosal epithelial cells at the site of initial 
inoculation. The virus is first sensed in infected cells, such as corneal epithelial cells and 
fibroblasts, by pattern recognition receptors (PRRs) that fall into several categories: Toll-like 
receptors (TLRs, such as TLR-2, TLR-3, TLR-7, TLR-8 and TLR-9), AIM2-like receptors, and 
nucleic acid sensors (such as RIG-I-like receptors, Stimulator of IFN genes (STING), IFI-16, and 
PKR)[79-86]. These PRRs activate intrinsic antiviral genes, like type-1 interferon (IFN) 
responses, which act in both autocrine and paracrine fashions to turn on interferon-inducible 
genes to limit viral replication and spread and to recruit inflammatory cells that can control 
HSV-1 replication[87]. These responses can also shut down translation in infected cells by 
phosphorylating eIF2α, turning on pro-apoptotic genes to induce cell death, and inducing PML 
protein expression to form Nuclear Dot 10 (ND10) bodies. To counter these innate responses, 
HSV-1 has mechanisms of its own— eIF2α phosphorylation is counteracted by ICP34.5, the 
viral US3 kinase counteracts host pro-apoptotic proteins by phosphorylating them, and ICP0 can 
degrade ND10 bodies to prevent chromatin repression [88-90].  The exact nature of the PRRs 
present, as well as their responses to recognizing viral patterns are very cell-type dependent, but 
have the net effect of limiting viral replication and spread. As mentioned previously, the viral 
tegument proteins and α gene products have many functions to counteract immunity, and a large 
portion of these are directed to counteract the host intrinsic detection and response, resulting in a 
push-and-pull of viral evasion vs. host defenses.  
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The release of type-I interferons and other cytokines, such as (IL)-1α, IL-1β, IL-6, IL-8, 
IFNγ, TNFα, MIP-1α, and IL-12 attract a large influx of neutrophils, macrophages, natural 
killers (NKs), dendritic cells (DCs), and γδ T cells to the initial site of infection in the cornea[91-
99]. These cells can recognize infected cells through multiple mechanisms, and are critical for 
viral control. Neutrophils respond very rapidly to inflammatory signals and play a role in 
limiting early viral spread in the cornea at least in part by producing pro-inflammatory cytokines 
and reactive-oxygen species[100]. Macrophages, NKs, and γδ T cells also respond early in 
ganglionic infection, and limit viral replication in the TG via production of effectors, such as 
iNOS, TNFα, and IFNγ[101-103]. Taken together, the intrinsic and innate immune responses 
serve to slow down or limit the early viral replication and spread to a level that is manageable, 
but as RAG/SCID mouse models and depletion studies show, the subsequent adaptive B and T 
cell responses that develop are key to ultimate control of viral replication and disease late in 
infection[104]. 
 
1.6.2 Adaptive immune response to HSV-1 
Upon primary infection, DCs acquire HSV-1 antigens and present them to naïve B and T 
cells within draining lymph nodes (DLN). The resulting HSV-specific B cells produce strong 
neutralizing antibodies which prevent viral particle infectivity, and by late infection help prevent 
viral spread[105]. To date, strong antibody responses have not been shown effective at 
preventing primary infections, which is one factor limiting an effective HSV-1 vaccine, however, 
some antibody responses are capable of reducing viral spread and disease in several models[106, 
107]. HSV-1 specific CD4+ and CD8+ T cell responses are also generated following primary 
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infection, and these cells traffic to both the site of primary infection at the mucosa, and the site of 
latency within the ganglia[68, 108, 109]. While CD4+ T cells are not suspected to play a direct 
role in viral latency control, they are instrumental in directing and aiding in the functionality of 
CD8+ T cell responses, discussed in the next section[110]. Of note is the fact that CD4+ T cells 
are also implicated in contributing to the inflammation and subsequent scarring that is seen in 
HSK-afflicted corneas[111, 112]. 
1.6.3 CD8+ T cell priming and memory 
CD8+ T cells directed against HSV-1 antigens detect short peptides (epitopes) that are 
presented bound to major histocompatibility complex class I (MHC-I) at the cell surface. In our 
mouse model of ocular infection, HSV-1 can be detected in the TG by 2 dpi, with declining viral 
titers coinciding with the peak CD8+ T cell infiltration into the ganglia at 8 dpi[113]. The HSV-
specific T cell infiltrate that enters ganglia is detectable as early as 5 dpi, and originates from the 
local draining lymph nodes (DLN)[114]. In early corneal infections, local and infiltrating DCs 
acquire HSV antigen either by direct HSV infection, or sampling of infected 
epithelial/fibroblasts in the cornea. DCs then deliver viral antigens to the DLN via lymphatic 
vessels, where they can be directly and/or cross-presented to naïve lymphocytes. CD8+ T cell 
priming by DCs requires proteosomal processing of cytosolic or endosomal antigens into 8-10aa 
peptides which are presented by MHC-I [115, 116]. However, recent investigations into the 
priming of CD8+ T cell responses to HSV infections suggest that both infected DCs and direct 
presentation by migratory DCs are dispensable for efficient CD8+ T cell priming[117, 118]. 
Indeed, in several viral models of CD8+ T cell priming there is a necessary degree of “shuffling” 
of viral antigen within the DLN from migratory DC subsets to DLN-resident CD8a+ DC subsets 
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for efficient CD8+ T cell priming and proliferation [119-121]. Recently primed CD8+ T cells that 
encounter antigen more often, and in the context of stronger costimulation and longer 
TCR/MHC-I contacts with presenting DCs also fare a better chance of proliferating and 
differentiating into memory CD8+ T cell populations that are key to antiviral responses[121]. 
There is also some evidence suggesting that in localized viral infections, naïve and developing 
CD8+ T cells compete for these TCR/MHC-I contacts within local DLN, and that limiting 
costimulation is a major factor that drives immunodominant CD8+ T cell responses [122]. 
After activation, antigen-specific CD8+ T cells undergo 1) clonal expansion during which 
they acquire effector functionality and antiviral properties, 2) contraction of the effector 
population through activation induced cell death, with the survival of a small percentage of 
memory cells, and 3) development of the memory CD8+ T cell population[123]. Generally 
speaking, memory CD8+ T cells are long-lived, antigen specific, and rapidly respond to their 
cognate antigen when encountered again[124]. Memory CD8+ T cells persist even in the absence 
of antigen, and remain at levels far higher than naïve precursor CD8+ T cell populations[125]. In 
the case of tissue-resident CD8+ T cell populations, like those found within the TG, the 
maturation into memory CD8+ T cells presumably involves the upregulation of homing receptors 
that keep these cells within the tissue. Of note, there is apparently no ganglionic infiltration of 
circulating central memory CD8+ T cells from the blood during viral latency[126]. 
1.6.4 CD8+ T exhaustion  
CD8+ T cells that respond to chronic or repeated viral infections may become exhausted 
due to repeated antigen exposure. In LCMV, HCV, HMPV and HIV models of CD8+ T cell 
exhaustion, the exhausted cells exhibit a reduced capacity to respond effectively when 
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encountering antigen[127-132]. Characteristic of exhausted CD8+ T cells is the loss of ability to 
produce effector cytokines, such as TNFα, IFNγ, and IL-2, as well as reduced capacity to release 
lytic granules into target cells[127]. Concurrent with the reduced effector status, there is a 
reduced ability of exhausted memory CD8+ T cells to proliferate, and an upregulation of 
suspected exhaustion markers such as PD-1, Tim3, LAG3, CD160, or 2B4[133-135]. Many 
factors — such as the amount and number of inhibitory receptors on exhausted cells, the amount 
of antigen detected over time, availability of CD4+ T cell help and the chronicity of infection — 
all influence the severity of exhaustion[127].  
1.6.5 The nature of CD8+ T cell responses during latency 
Evidence suggests that sporadic phase 1 viral gene expression in the latently infected 
ganglia is immune-recognized, particularly by a persistent resident ganglionic CD8+ T cell 
population [66, 68, 136].  Indeed, the B6 mouse model of HSV-1 latency has been under 
particular scrutiny, with the initial viral occupancy of the ganglia accompanied by a large 
infiltration of immune cells, including both CD4+ and CD8+ T cells. The magnitude of this 
immune infiltrate peaks near the onset of latency and then rapidly contracts, leaving a persistent 
low-level infiltrate that is maintained for the life of the host. Persisting ganglionic immune 
infiltrates associated with HSV-1 latency have also been seen in other model species and in 
humans [78, 137-140].  The ganglionic CD8+ T cells in mice show markers of an activated 
effector memory phenotype at early stages, which is capable of reducing HSV-1 reactivation 
events in ex vivo cultures of latently infected ganglia[68, 141].   
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We and others have proposed that the ganglionic CD8+ T cell infiltrate surveys the 
ganglia for reactivation events, eventually tipping the lytic/latent balance of the virus towards the 
latent state[142]. If phase 1 or early phase 2 gene expression is detected in neurons at latency, 
and CD8+ T cells respond rapidly, several effector mechanisms have been identified that can 
hinder viral lytic replication. This is accomplished through an IFNγ-mediated reduction of HSV-
1 gene expression and a Granzyme B/perforin dependent degradation of ICP4, both of which are 
accomplished without inducing neuronal apoptosis, suggesting that rapid immune control 
following recognition of protein expression in latently infected ganglia is vital to preventing 
reactivation[78, 141].  Successful viral reactivation then, likely results from a failure of CD8+ T 
cell control of viral gene expression from progressing into late phase 2, wherein viral immune 
evasion genes are abundant within the neuron, and capable of blocking CD8+ T cell responses. 
Specifically, several mechanisms have been identified, including: viral ICP47, γ34.5, and US3 
kinase, which are capable of preventing effective MHC-I presentation, and UL13, which can 
downregulate neuronal expression of the T-cell chemoattractant CXCL9[49, 50, 143-145]. 
1.6.6 Characteristics of gB CD8+ T cell immunodominance 
The C57BL/6 (B6) mouse ocular HSV infection model has been particularly useful to 
explore cellular CD8+ T cell directed immunity, because the entire HSV-1 specific CD8+ T cell 
target repertoire has been described [77].  In B6 mice, the CD8+ T cell repertoire developed to 
HSV-1 is highly skewed, as a single immunodominant epitope on the essential viral glycoprotein 
B (gB) that accounts for approximately half of all HSV-1 specific CD8+ T cells (gB-CD8s). 
These gB-CD8s are directed to amino acids 498-505 of gB (SSIEFARL, henceforth referred to 
as gB498-505).  The other HSV-1 specific CD8
+ T cell populations (collectively termed non-gB-
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CD8s) recognize 19 additional subdominant viral epitopes on only 12 viral proteins [77].  The 
approximate 1:1 ratio of HSV gB-CD8s to non-gB-CD8s is maintained systemically, in the 
corresponding lymph nodes, the spleen, and in the TG during acute peak infiltrate and in the 
contracted population during latency [113, 146]. However, while gB-CD8s during HSV-1 
latency show an activated and highly functional phenotype that responds to antigen stimulation, 
non-gB-CD8 populations show a partial loss of function, such that a significant fraction do not 
respond to antigen stimulation.   Loss of function in the non-gB-CD8 population resembles 
functional exhaustion in that it is associated with increased expression of the inhibitory receptor 
programed death-1 (PD-1) and is regulated by IL-10 [147, 148].  Thus, the TCR repertoire of 
functional CD8+ T cells narrows by a process akin to functional exhaustion of subdominant 
CD8+ T cells within the latently infected TG.  
  22 
2.0  SPECIFIC AIMS 
HSV-1 specific CD8+ T cell responses in the latently infected ganglia are of special interest due 
to their ability to monitor viral latency for viral gene expression and prevent reactivation events 
from progressing.  It is of vital importance to understand CD8+ T cell responses in this context, 
and how they interact with viral proteins expressed both during latency.  We hope that this 
knowledge will aid in developing strategies that can manipulate the functional T cell repertoire 
and enhance monitoring of viral latency. 
 
Determine the influence of an HSV-1 immunodominant CD8+ T cell epitope on target 
hierarchy and function of subdominant CD8+ T cells during viral latency 
 The entire subdominant CD8+ T cell repertoire of HSV-1 was recently identified in B6 
mice, and has been shown to be minimally functional when compared to the WT HSV-1 
response. Developing a mutant that lacks this epitope allows us to investigate thoroughly the 
nature of a compensatory response when an immunodominant epitope is removed from the viral 
genome We hypothesize that select subdominant HSV-1 responses will expand numerically and 
functionally to fill the TG-resident memory CD8+ T compartment. 
 
Investigate the role that antigen expression kinetics play in generating and maintaining 
CD8+ T cell responses during HSV-1 latency. 
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 During HSV-1 latency, emerging evidence supports the model that viral antigen is 
expressed at very low levels and is monitored by a protective ganglionic-resident CD8+ T cell 
population. We hypothesize that altering the promoter that drives CD8+ T cell epitopes during 
CD8+ T cell priming and latency will alter the magnitude and functionality of CD8+ T cell 
responses.  
 
Prime a ganglionic HSV-1 specific CD8+ T cell response using AAV or PRV vectors 
 HSV-1 replication is controlled in part by effector CD8+ T cell responses within the 
ganglia prior to the establishment of stable latency. Having a pre-established tissue-resident 
memory CD8+ T cell population could reduce viral burden upon HSV-1 infection. We 
hypothesize that priming a tissue-resident CD8+ T cell population in the ganglia will be 
protective against subsequent HSV-1 infections. 
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3.0  MATERIALS AND METHODS 
3.1 VIRUS AND CELLS 
Vero cells (ATCC, Manassas, Virginia), SV40-transformed B6 embryo fibroblast cell 
line B6WT3 (MHC-I compatible with C57BL/6 mice; [149]), and gB-Vero (Vero cells stably 
transfected with a plasmid expressing gB from the native gB promoter; obtained from Dr. 
William Goins, University of Pittsburgh) were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin-G (100 units/ml), 
streptomycin (100 mg/ml) and fungizone (250 mg/ml).  All HSV-1 are based on the KOS strain 
originally obtained from a master stock obtained from P Schaffer. This strain was recently 
sequenced (GenBank JQ780693.1) [150]. 
Pseudorabies virus (PRV) used in this study were generated using a Becker-strain 
bacteria artificial chromosome (BAC) (kind gift from Lynn Enquist, Princeton University) [151] 
PRV expressing HSV-1 gB494-509 in a thymidine kinase (TK) knockout virus was developed in 
the E. Coli strain GS1783 by placing a kanamycin-resistance cassette containing monomeric red 
fluorescent protein in frame with TK at site 59,595 (Genbank JF797219.1) followed by a CMV 
promoter driving expression of 4 repeats of HSV-1 gB494-509. This cassette was amplified using 
the following primers: Forward, 5'-GCGGCAACCTGGTGGTGGCCTCGCT 
GGACCCGGACGAGCACATGGCCTCCTCCGAGGACGTCAT-3'; Reverse, 5’- 
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TCAGGTAGCGCGACGTGTTGACCAGCATGGCGTAGACGTTCCTCGCGAGGGATCGG
CTAGAGTC -3’ and inserted into the PRV BAC using recombineering [152]. The kanamycin-
resistance cassette was resolved using two-step red-mediated recombination, with a resultant 
disruption of the TK gene. PRV was propagated to high titer in PK15 (porcine kidney 15, ATCC 
CCL-33) epithelial cells, purified as done for HSV, and gB-peptide expression confirmed by 
stimulation of gB-specific T cells, as described below. 
Adeno-Associated Virus (AAV) fluorescent reporter constructs were purchased from 
Vector Biolabs. 
 
3.2 VIRUS PURIFICATION  
All HSV-1 and PRV used in these studies were purified from infected Vero cell (for 
HSV-1) or PK15 (for PRV) monolayers in T175 flasks. After cytopathic effect in >90% of cells, 
NaCl is added to a final concentration of 0.45M in culture media, rocked for 1 hour, and 
centrifuged at 2000g for 10min to pellet cellular debris. Supernatants are passed through 0.8um 
filters, then used to overlay 1-2mL of a 50% sucrose cushion, and pelleted at 142,000g for 1h. 
After removing most supernatant, the virus pellet was carefully resuspended in a 500uL volume 
of the remaining sucrose cushion and media. 
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3.3 DERIVATION OF HSV-1 WITH GB498-505 MUTATIONS 
DNAs were amplified by polymerase chain reactions (PCR) using a proofreading 
polymerase [Expand (Roche) or Primestar (Takara)] with “Hot start” conditions and in reactions 
containing 4% DMSO, as detailed previously [153].   A plasmid was derived in which genomic 
recombination into HSV-1 would replace the approximately N terminal half of the gB coding 
sequence with EGFP, using a pUC19-based plasmid (gC Rescue construct, Fig 1) detailed 
previously [153] containing HSV-1 DNA from 54,475bp to 56,464bp (sequences given in 
reference to HSV-1 KOS Genbank JQ780693.1) containing the gB promoter and partial gB 
coding region. The construct had a unique EcoRI flanking at 54,475 and unique HindIII site 
flanked 56,464, and a unique AvrII site at position 58,476bp, immediately upstream of the gB 
ORF start and designed not to alter the coding of the upstream UL28 protein. The AvrII-EcoRI 
fragment of this plasmid was replaced with a PCR fragment encoding gB residues 507 to the stop 
codon, generated using primers 5’-GCGCCTAGGCTCGGATCCCAGTTTACGTACAAC-3’ 
and 5’-GAGCGGAATTCATTTACAACAAACCCCCCATCA-3’ (restriction sites underlined).  
This construct (termed pgBp-gBend) was then further modified by inserting a PCR-amplified 
fragment containing EGFP using the primers: 5’ 
CCCTAGGCTACCTGACGGCGGGCACGACGG 3’ and 5’ 
CGTAGGATCCTTACTTGTACAGCTCGTC 3’.  The BamHI-AvrII fragment was inserted into 
BamHI-AvrII digested pgBp-gBend, resulting in the flanking of EGFP by the gB promoter 
sequences, and sequence encoding gB residues 507- 904 (Fig 1).  When this linearized plasmid 
was then cotransfected with infectious HSV-1 DNA on gB-Vero cells, recombinant viruses 
showing EGFP positivity were selected and grown on complementing gB-Vero cells.  Infectious 
HSV-1 KOS DNA was obtained using methods outlined previously [153].   Recombinant viruses 
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(HSV-1 gB-null-EGFP) were then verified for correct DNA insertion by DNA sequencing of the 
junctions and by Southern blot analyses.   
Plasmid pgBp-gBend was digested with AvrII-SnaBI to remove the EGFP cassette, and 
replaced with PCR amplified sequence encoding gB residues 1-509 with altered residues in the 
gB SSIEFARL motif (Table 1). The primers shown in table 1 were used in conjunction with the 
primer 5’  GCCCTAGGCTACCTGACGGGGGGCACGACGGGCCCCCGTAG 3’.  Each PCR 
was then cloned as an AvrII-SnaBI fragment and sequence verified.  Linearized plasmids were 
then individually cotransfected with HSV-1 gB-null-EGFP infectious DNA on Vero cells, and 
HSV-1 recombinants replicating on Vero cells, lacking GFP expression, and containing the 
mutations in the gB498-505 region were plaque-purified. HSV-1 containing gB L505A (designated 
HSV L8A) and gB S498L (designated HSV S1L) were derived. We also derived expression 
plasmids for each epitope-mutated gB protein by placing the AvrII-EcoRI fragment containing 
the entire altered gB protein coding region into the vector pEGFP-C3, digested with NheI and 
EcoRI to place gB under the control of the human cytomegalovirus Immediate early (CMV IE) 
promoter and SV40 polyadenylation signals.   
3.4 CONSTRUCTION OF HSV-1 WITH GB498-505 EXPRESSED FROM VARIOUS 
PROMOTERS 
DNAs were amplified by polymerase chain reactions (PCR) using a proofreading 
polymerase [Primestar (Takara)] with reactions containing 4% DMSO, as detailed previously 
[153].  The constructs used to derive recombinant viruses were developed in a manner similar to 
that detailed previously in which gene cassettes were inserted into the nonessential gC locus 
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encoded by UL44 [153].  Briefly, the parent vector was a previously detailed plasmid that 
contained the gC promoter driving expression of EGFP inserted neat the ATG of UL44, followed 
by part of the gC ORF[154].  The EGFP gene was an NheI - XbaI fragment obtained from the 
plasmid EGFP N-1 that is translationally stopped before the gC ORF.  To develop a gB498-505 
epitope fusion, two complementary oligonucleotides were purchased from IDT Inc. the sense 
oligo - 5’ –  GAT CCC ACC ATG GCG CAT AAG ACC ACC TCC TCC ATC GAG TTC 
GCC AGG CTG CAG TTT ACG TAC AAC CAC AA-3’ - and the antisense oligo - 5’ GATC  
TTGTGGTTGTACGTAAACTGCAGCCTGGCGAACTCGATGGAGGAGGTGGTCTTATGC
GCCATGGTGG-3’ were hybridized together at 70oC for 5min, slow cooled, phosphorylated 
using T4 polynucleotide kinase, and ligated together overnight with T4 DNA ligase at room 
temperature. Reaction was then doubled in volume, heat inactivated and digested with BamHI 
and BglII to remove head-to-head and tail-to-tail concatemers. Following electrophoresis on 6% 
PAGE gels, fragments corresponding to different copies of the repeats were extracted by 
electroelution, purified and then ligated into the unique BamHI site immediately upstream of 
EGFP in the plasmid pgC-EGFP.  A clone (gCp-pep4-EGFP) containing one or four copies was 
selected for further use that contained the peptide corresponding to gB495-511, expressed in frame 
with EGFP and with an initiating start codon (Fig 1) (-TMAHKTTSSIEFARLQFTYNHKDP-)4-
GFP.  The different promoters used in this work, with the exception of LAT, were generated by 
PCR methods to contain a minimum of 500 bp of sequence immediately upstream of the 
respective ORF ATG using primers (Table 1) with a 5’ additional sequence encoding flanking 
unique HindIII site distally and a unique BamHI site at the proximal end of the promoter. These 
were cloned into the vector gCp-pep4-EGFP cut with BamHI and HindIII.  Finally, DNA 
containing monomeric fluorescent protein mRFP with its bovine growth hormone 
  29 
polyadenylation A sequence was generated from the plasmid pgC-RFP/pgB-EGFP detailed 
previously (Ramachandran et al.  2008) and cloned into the unique NheI-and HindIII sites to 
place the red fluorescent protein gene downstream of the gC promoter.  For the HSV-1 LAT 
promoter, a SacI – BamHI DNA fragment of the vector pBS-KS:LAP1 (a kind gift of David 
Bloom, University of Florida) representing bp 117,396 to 119,289 of HSV strain 17+, including 
the LAT promoter and LAT 5’ exon region) was cloned into the gCp-pep4-EGFP cut with 
BamHI and SacI, and then subjected to cloning of the mRFP protein as just detailed for other 
constructs.  In all constructs, sequences corresponding to the promoter of gC drives the 
expression of the mRFP protein followed by poly A signal. This is followed by the selected 
promoter sequence driving a 4mer repeat of a peptide that contains the gB494-511 in frame with 
the EGFP protein. This is followed by a portion of the gC open reading frame, and the flanking 
gC promoter and gC ORF portion permit recombination into the gC locus.  
Recombinant viruses were derived by cotransfection of plasmids just outlined after 
linearization with SspI or EcoRI with HSV-1 KOS S1L infectious DNA in a manner similar to 
that detailed previously[153, 155].  Virus plaques were then selected based on gain of red 
fluorescence and plaque purified to homogeneity as determined by fluorescence.  We did not use 
EGFP to select, as the n terminal fusion of the peptide reduced fluorescence to low levels that 
were difficult to visualize.   
3.5 ANIMAL INFECTION  
Six to eight week old female C57BL/6 mice (Purchased from Jackson Labs) or gB-T1 
mice [156] were used in these studies.  All animal experiments were conducted in accordance 
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with protocols approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee.  Corneas of anesthetized mice were scarified using a 30g prior to HSV-1 corneal 
infections, as detailed previously [153].  HSV-1 (1 x 105 PFU of purified HSV-1 in 2-3 µl RPMI 
media) was then applied to each eye. When infections were performed in the mouse flank, a 
small (5mm x 5mm) region of skin was denuded of hair, and the same amount of virus was 
applied to abraded skin.  For AAV, corneas were abraded as in HSV-1 infections, with 1*10^10 
genome copies/eye applied. 
3.6 TISSUE PREPARATION 
Tissues for subsequent flow cytometry analyses were obtained from anesthetized mice 
injected first i.p. with 0.3 ml of 1000 U/ml heparin (Sigma-Aldrich, St. Louis, MO) and then 
euthanized by exsanguination.  Lymph nodes, TG were removed and subsequently digested in 
RPMI containing 10% fetal bovine serum and 400 U/ml collagenase type I (Sigma-Aldrich) for 
45-60 minutes at 37oC.  Tissues were mechanically dissociated and triturated into single-cell 
suspensions and then filtered through a 40 µm nylon cell strainer (BD Biosciences, Bedford, 
MA). Spleens were treated with red blood cell lysis buffer (BD Pharm Lyse) for three minutes 
prior to analyses. Corneas were excised, processed under a dissecting microscope to separate the 
cornea and conjunctival tissue, and mounted onto microscope slides. 
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3.7 EX VIVO REACTIVATION STUDIES 
For ex vivo reactivation, TG samples were first rendered into single cell suspensions as 
just detailed, but without filtering. In cases where endogenous CD8+ T cells were depleted, we 
used antibody/complement mediated lysis using Low-Tox M rabbit complement (Cedarlane) and 
anti CD8, as previously described[78]. The efficiency of depletion was assessed by flow 
cytometry and was considered effective if >95% of the CD8+ T cells were depleted. Mock 
depleted suspensions used an IgG isotype control under the same conditions.  Single-cell TG 
suspensions were then plated at one-fifth TG equivalents per well in 48-well culture plates in 400 
l of DMEM containing 10% FBS, 10 mM HEPES buffer, 10 U/ml recombinant murine IL-2 
(R&D Systems), and 50 M 2-mercaptoethanol.  Where indicated, cultures were supplemented 
with exogenous expanded gB-CD8s made as described previously at 2 x 104 CD8+ T cells/well 
[141]. TG cultures were monitored for reactivation by testing 50uL culture supernatant fluid for 
live virus by standard viral plaque assays as previously described [78]. The 50uL was replaced 
each time with fresh media.  Supernatants were tested every two days for a total of ten days in 
culture.  Data are represented as the percent of wells that were positive for viral reactivation. 
 
3.8 CD8+ T CELL EXPANSION AND STIMULATION 
CD8+ T cells specific for gB498-505 were expanded from TG preparations taken 8 days post 
infection (dpi) from mice infected with HSV-1, as detailed previously [141], or with collagen-
dissociated suspensions of TGs. Cultures were maintained for up to 10 days, followed by MACS 
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bead purification of the CD8+ T cells.  Resulting populations were >95% CD3+, CD8+, and 
positive for gB498-505/H-2K
B tetramer.  For preparing target B6WT3 fibroblasts, the (WT) and 
mutant gB proteins were expressed in B6WT3 (1 x 105 cells) transfections with 5 g of plasmids 
expressing each gB protein or the epitope mutant protein under the CMV IE promoter.  At 24 
hours post-transfection, co-cultures for stimulations were established, with 5 x 104 expanded gB-
CD8+ or CD8+ T cells obtained from the TG of HSV-1 infected gB-T1 mice added per 1 x 105 
target B6WT3 cells. Co-cultures were maintained for 6 h in the presence of Brefeldin A, and 
then subsequently stained for surface CD45, CD8 and intracellular IFNγ and/or TNFα as markers 
of activation.   
T cell phenotypic characterization by flow cytometry was performed essentially as 
detailed previously [77].  Single cell suspensions of TGs and spleens were stained with 
antibodies to CD45, CD3, and CD8, and with tetramers for 1 hr at room temperature prior to 
fixing for 20 minutes with Cytofix/Cytoperm (BD Biosciences, Bedford, MA). Washed cells 
were then analyzed by flow cytometry.  CD8+ T cell recognition of HSV-1 target antigens was 
determined by pulsing cultured B6WT3 fibroblasts with the respective peptide [77] at a 
concentration of 1 µg/ml for 30 min at 37oC/5% CO2. Alternatively, B6WT3 fibroblasts were 
infected for 6-12 hours at an MOI of 5 with recombinant HSV-1 or PRV, and then virus was 
UV-inactivated prior to stimulation.  The dispersed TG or spleen cells were added to peptide-
pulsed or infected fibroblasts in the presence of Brefeldin A and anti-CD107a (BD clone 1D4B) 
for 6 hr at 37oC/5% CO2.  After stimulation, cells were stained for surface expression of anti-
CD45 and CD8, permeabilized and fixed using Cytofix/Cytoperm and then subjected to 
intracellular stain for IFNγ and TNF.  The peptides used in this work were detailed previously 
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[77]. For each peptide, both TGs from a minimal total of five mice per peptide were separately 
analyzed for reactivity. 
3.9 ANTIBODY REAGENTS AND FLOW CYTOMETRY 
Phycoerythrin (PE)-conjugated or BV421-conjugated H-2Kb tetramers complexed with 
the gB498-505, RR1982-989, or RR1822-829 peptide were provided by the National Institute of Allergy 
and Infectious Diseases Tetramer Core Facility (Emory University Vaccine Center, Atlanta, 
GA). Efluor-450 conjugated anti-CD3 (clone 17A2) was purchased from eBioscience. Pacific-
Blue-conjugated anti-CD8 (clone 53-6.7), APC-conjugated anti- IFNγ (clone XMG1.2), PerCP-
conjugated anti-CD45 (clone 30-F11), PE-Cy7-conjugated anti-TNF (clone MP6-XT22), APC-
conjugated anti-granzyme B (clone GB11), and BD Cytofix/Cytoperm Fixation/Permeabilization 
Solution Kit were purchased from BD Pharmingen (San Diego, CA).  The appropriate isotype 
control antibodies were purchased from the same company used for the reactive antibody and 
used as controls for intracellular staining.  All flow cytometry samples were collected on BD 
FACSAria cytometer and analyzed by FACSDiva and/or FlowJo software.  
3.10 BRDU PROLIFERATION ASSAY 
Latently infected mice (28-34 dpi) were pulsed for two days prior to harvest with 
1mg/mouse of BrdU in 0.1ml PBS via i.p. injection. The TGs were harvested at 48hr later and 
cells were prepared for flow cytometric analysis. An FITC BrdU Flow Kit (BD Pharmingen, San 
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Diego, CA) was used as per manufacturer instructions, briefly: TG cells were washed twice with 
FACS buffer (1% FBS, 0.1% sodium azide in PBS) prior to surface antibody staining in the 
presence of Fc block. Following surface staining, cells were permeabilized with 
Cytofix/Cytoperm solution for 20 min on ice and then Cytofix/Cytoperm Plus for 10 minutes on 
ice. After being washed, cells were treated with 30 µg of DNAse for 1hr at 37C, washed with 
1X BD Perm/Wash solution, and cells were then incubated for 30 minutes in BrdU antibody 
diluted in 1X BD Perm/Wash. After labeling, suspensions were washed with 1X Perm/Wash and 
resuspended in FACS buffer for analysis by flow cytometry.  
3.11 MURINE OCULAR DISEASE SCORING 
Corneal reflex was tested and recorded as positive (1) or negative (0) by loosely holding 
the mouse and touching all areas of the cornea with a surgical spear, being careful to avoid 
touching the eyelashes and whiskers. A loss of BR indicated a complete loss of corneal sensation 
such that the mouse failed to blink when any area of the cornea was touched. A positive reflex 
indicated retention of some degree of sensation such that the mouse blinked when at least one 
area of the cornea was touched. 
Corneal disease was monitored by at least two investigators in using slit-lamp 
examination after PRV or HSV-1 corneal infection. HSK, characterized by corneal opacity and 
neovascularization, was monitored by slit-lamp examination and scored based on opacity: 0.5, 
any imperfection of the cornea; 1, mild corneal haze; 2, moderate opacity; 2.5, moderate opacity 
with regional dense opacity; 3, severe, dense opacity obscuring the iris; 3.5, severe, dense 
opacity with corneal ulcer; and 4, corneal perforation.  
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Neovascularization was determined visually by dividing the cornea into 4 quadrants, and 
each quadrant was scored as 0 (no vessels visible), 1 (vessels extending into one quadrant of the 
cornea), 2 (vessels extending into 2 quadrants of the cornea), 3 (vessels extending into 3 
quadrants of the cornea) or 4 (severe vascularization in all quadrants or extending significantly 
into the central cornea). Discrepancies between observers were averaged. 
3.12 QUANTITATIVE REAL-TIME PCR 
HSV-1 or PRV genome copy number in infected TG was determined by quantitative real-time 
PCR as previously described using primers that recognize the sequences of the gH gene [157]. 
3.13 STATISTICAL ANALYSIS 
 
All statistical analyses were performed using GraphPad Prism software package.  The specific 
statistical applications are shown in the legends to each figure.  
3.14 ETHICS STATEMENT 
All animal experiments were conducted in accordance with protocol # 15076444, 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee. This 
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protocol meets the standards for humane animal care and use as set by the Animal Welfare Act 
and the NIH Guide for the Care and Use of Laboratory Animals. 
 
  37 
4.0  INFLUENCE OF AN IMMUNODOMINANT HSV-1 CD8+ T CELL EPITOPE ON 
THE TARGET HIERARCHY AND FUNCTION OF SUBDOMINANT CD8+ T CELLS 
The CD8+ T cell dominance hierarchy seen in the B6 mouse model and the strong 
dominance of the HSV-1 gB498-505 epitope is remarkable.  It is not clear why the gB498-505 epitope 
is so immunodominant, as the position of an epitope within the dominance hierarchy can be 
influenced by many factors [158].  However, while during HSV-1 latency gB-CD8s show an 
activated and highly functional phenotype that responds to antigen stimulation and is capable of 
reducing HSV-1 reactivation events in ex vivo cultures, non-gB-CD8 populations show a major 
loss of function, such that a significant fraction cannot respond to antigen stimulation, [77, 141]. 
These observations suggest a role of gB-CD8s in regulating the HSV-1 latent/lytic decisions in 
vivo. The combination of a strongly immunodominant epitope and a completely defined TCR 
repertoire make HSV-1 an excellent model to investigate the effect of removing an 
immunodominant epitope on the resulting non-gB-CD8 repertoire and changes in functionality 
associated with the latent state. To understand how dominance hierarchies relate to CD8+ T cell 
function during latency, we characterized the TG-associated CD8+ T cells following corneal 
infection with a recombinant HSV-1 lacking the immunodominant gB498-505 epitope (S1L). 
Gaining insights into how CD8+ T cell-peptide recognition dynamics during the establishment 
and maintenance of latency alter functionality may lead to strategies that improve ganglionic 
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immune infiltrates and increase protection from HSV-1 reactivation and subsequent disease 
[159].  
 
4.1 MUTATIONS IN HSV-1 GB498-505 PREVENT ANTIGEN RECOGNITION BY GB-
CD8S 
A series of gB mutants in the 498-505 amino acid region was generated and evaluated for 
recognition by gB-CD8s.  The eight gB mutations (Table 1) included: mutations of the predicted 
MHC-I anchoring residues in the peptide (L8A, S1L, S1G, L8A/S1G, and L8A/R7K); mutations 
in the predicted T cell receptor binding region (F5L and S1G/I3A): and a mutation that changed 
the HSV-1 gB498-505 region to that of VZV, S1G/l3N/F5L/E4S (SIFE).  The L8A mutation was 
previously reported (referred to as L505A) to abrogate gB-CD8 development upon flank skin 
infection of B6 mice [160].  We found that most of the eight mutant gB genes expressed a 
protein from plasmids that were detected by gB-specific antibodies of the size expected for gB 
(Fig 5).  When each mutant gB protein was expressed in transfected B6WT3 fibroblasts, only 
wild-type (WT) gB could stimulate the production of intracellular IFNγ in an expanded 
population of gB-CD8s (Fig 5).  While only a modest fraction of gB-CD8s showed activation, it 
was clear that all eight mutations of the gB498-505 region mostly or completely abrogated gB-CD8 
recognition.  
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Table 1. Primer sequences to generate mutations in the gB epitope 
Name Mutation Reverse primers used* 
WT SSIEFARL (none) 5’ GTT GTA CGT AAA CTG CAG CCT GGC GAA CTC GAT 
GGA GGA GGT GGT CTT GAT GCG CTC CA 3’ 
L8A SSIEFARA 5 ‘ GTT GTA CGT AAA CTG agc CCT GGC GAA CTC GAT GGA 
GGA GGT GGT CTT GAT GCG CTC CA 3’ 
F5L SSIELARL 5’ GTT GTA CGT AAA CTG CAG CCT GGC cAA CTC GAT 
GGA GGT GGT CTT GAT GCG CTC CA 3’ 
 S1G GSIEFARL 5’ GTT GTA CGT AAA CTG CAG CCT GGC GAA CTC GAT 
GGA ccc GGT CTT GAT GCG CTC CA 3’ 
S1L LSIEFARL 5’ GTT GTA CGT AAA CTG CAG CCT GGC GAA CTC GAT 
GGA caa GGT GGT CTT GAT GCG CTC CA 3’ 
S1G/L8A GSIEFARA 5’ GTT GTA CGT AAA CGT agc CCT GGC GAA CTC GAT GGA 
ccc GGT GGT CTT GAT GCG CTC CA 3’ 
S1G/I3A GSAEFARL 5’ GTT GTA CGT AAA CTG CAG CCT GGC GAA CTC Ggc 
GGA ccc GGT GGT CTT GAT GCG CTC CA 3’ 
L8A/R7K SSIEFAKA 5’ GTT GTA CGT AAA CGT agc CtT GGC GAA CTC GAT GGA 
GGA GGT GGT CTT GAT GCG CTC CA 3’ 
S1G/I3N/F5L/E4S 
(SIFE) 
GSNSLARL 5’ GTT GTA CGT AAA Ctg CAG CCT GGC cAA gct GtT GGA 
ccc GGT GGT CTT GAT GCG CTC CA 3’ 
*The restriction site of SnaBI used in cloning is shown in bold. Changes from the wild type 
sequence are shown in lower case letters. 
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Figure 5. Mutant gB proteins and recognition by gB-CD8s 
Untreated B6WT3 cells (mock) or cells transfected with plasmids to express WT gB or gB498-505 epitope 
mutants were incubated for eighteen hours.  The labeling of the mutations is as depicted in Table 1; WT is a 
plasmid which went through the mutagenesis procedure without changes.  Cells were harvested for 
expression analysis by immunoblotting using a monoclonal gB-specific antibody (lower panel) or, in 
parallel, transfected cells were combined with 5x104 gB-CD8s from an endogenously expanded clone and 
stimulated for 5 h in the presence of Brefeldin A.  gB-CD8s were surface stained for CD45 and CD8, 
permeabilized, and stained for intracellular IFNγ.  The graph depicts one of two representative experiments, 
with the mean percent of IFNγ+ cells (n = 2/group) and standard error of the mean (SEM) for each 
stimulation. Studies completed by Sarah Bidula. 
 
HSV-1 recombinants containing each mutation were developed (Fig 6) by rescue of the 
growth of a gB-null-EGFP virus on gB-complementing Vero cells, and all yielded virus that 
could form plaques on non-complementing cells. Recombinant HSV-1 with the following 
mutations in gB formed small plaques, indicating they were growth-impaired: S1G, F5L, 
S1G/I3A, S1G/L8A, and S1G/I3N/F5L/E4S (Table 1).  This was confirmed following ocular 
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infection of B6 mice, where low viral replication was detected at 4 dpi within the TG of mice 
(Fig 7A).  These impaired viruses were not studied further. However, the S1L and L8A viruses 
could replicate to levels not significantly different from WT HSV-1 at 4 dpi in the TG (Fig 7A). 
They also establish equivalent latent genomic loads in the TG at 8 dpi (Fig 7B), and replicate to 
the levels of parental WT virus in both multi-step (infected at MOI of 0.01) and single step 
(infected at MOI of 10) growth curves in cultured Vero cells (Fig 7C).  Since viral load and 
fitness in mice might influence CD8+ T cell hierarchy [161], we initially focused on these two 
HSV-1 mutants and then conducted detailed studies on HSV-1 S1L. 
 
 
Figure 6. Construction of gB null virus and of HSV-1 with gB498-505 mutations   
Line i represents the parental plasmid used for derivation of the constructs in this study, detailed previously 
[47]. Line iii represents the replacement of the gB ORF with EGFP followed by the remaining part of the 
gB ORF from residue 509 to the end (gB ORF Back) that was developed to obtain a gB null EGFP virus.  
Line ii represents the HSV genome and the approximate coding position and direction of the gene for gB.  
Line iv represents the replacement gB genes and the site of the epitope mutations with respect to the SnaBI 
site used for derivation, as detailed in the text.  AvrII and SnaBI are restriction sites used to clone the 
replacing region of gB.    
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Figure 7. Growth of HSV gB mutants in vitro and in vivo 
(A) Virus growth in the TG of B6 mice was determined at 4 days post ocular infection with 1x105 PFU of 
either HSV-1 WT or HSV-1 containing the gB498-505 epitope mutants detailed in table 1.  TG were harvested 
and subjected to three freeze thaw cycles and infectious virus released into the supernatant was titrated on 
Vero cells. The graph represents the mean virus titer for each virus ± SEM of the mean (n = 5 mice). This is 
a representative of two separate studies with similar results.   (B) Genome copy number determined by 
qPCR in the TG of mice infected with HSV-1 WT, S1L, or L8A following harvest at day 8 post ocular 
infection (n=10). Values are representative of the total copies per TG.    (C) Monolayer cultures of Vero 
cells were infected at a multiplicity of infection (MOI) of 10 PFU/cell (high MOI Growth Curve) or 0.01 
PFU/cell (Low MOI Growth Curve) respectively with HSV-1 WT, S1L, or L8A.  At the indicated hours 
post-infection, cells and supernatants were pooled, subjected to three freeze–thaw cycles and the viral titers 
were determined by plaque assay. The mean PFU/culture ± standard error of the means (SEM) is shown at 
each time. Studies completed by Sarah Bidula and Srividya R. Ramachandran. 
4.2 HSV-1 LACKING THE GB498-505 EPITOPE INDUCES AN EQUIVALENT TG 
CD8+ T CELL RESPONSE THAT IS NOT DIRECTED TO GB498-505 
Following ocular infection of B6 mice, the peak CD8+ T cell infiltration in the TG occurs 
at 8 dpi and subsequently contracts to a low but persistent level that remains for the life of the 
host.  The total CD8+ T cell infiltrates into TG of mice that received corneal infections with 
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HSV-1 S1L and L8A were not statistically different from those induced by WT HSV-1 infection 
(Fig 8A).  However, while approximately half of the CD8+ T cells infiltrating TG infected with 
WT HSV-1 [114] stained positively with gB498-505 H2-K
B tetramers, CD8+ T cells infiltrating TG 
infected with HSV-1 S1L and L8A showed extremely low gB498-505 tetramer staining (Fig 8B).  
The gB498-505 tetramer positive cells were also virtually undetectable in spleens and the local 
draining lymph nodes (DLN) of S1L infected mice (Fig 8C and 8D). This suggests that there is 
an HSV-specific CD8+ T cell response in the TG that compensates for the loss of the 
immunodominant gB-CD8 population, as seen previously[160]. 
 
 
Figure 8. Acute CD8+ T cell infiltrates in the ganglia of mice after corneal infection with WT HSV-1 
or recombinant HSV-1 containing gB498-505 mutations.   
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Corneas of mice were infected with 1x105 PFU/eye of HSV-1 WT, S1L, or L8A.  At 8 dpi (peak CD8+ T 
cell infiltrate), the TG, spleen, or DLN were dissociated into single cell suspensions and surface stained 
with antibodies to CD45, CD3, CD8 and with MHC-I gB498-505 tetramer as detailed in Methods.  Cells were 
analyzed by flow cytometry, and the data are presented as the mean +/- SEM (n=5 mice, 10 TGs) of (A) 
absolute number of CD3+CD8+ T cells per TG, (B) the percent of gB498-505 tetramer positive CD8+ T cells in 
each TG, or (C, D) the total number of gB498-505 tetramer specific cells per spleen and local DLN.  The 
experiment shown is representative of three additional experiments, all producing similar results.  The 
absolute numbers of CD8+ T cells induced in the TG with each virus were not statistically different as 
shown by a one-way ANOVA followed by Tukey’s posttest (p=0.58).  
 
 
Failure of gB-CD8s to recognize the S1L mutation was further assessed by testing the 
ability of exogenous gB-CD8s to block HSV-1 S1L reactivation in ex vivo ganglionic explant 
cultures.  TG of B6 mice harboring equivalent WT HSV-1 or S1L virus were excised at latency 
(34 dpi), dispersed with collagenase, depleted of endogenous CD8+ T cells and then plated in 1/5 
TG cell equivalents per culture well, either alone or with 2x104 gB-CD8s from a previously 
described clone, all under conditions that maintain T cell viability [141].  In the absence of CD8+ 
T cells, approximately 50-60% of TG cultures showed HSV-1 reactivation and virus release into 
the media, with reactivation frequency that was not statistically different in TG infected with WT 
and S1L virus (Fig. 9A). These data establish that HSV-1 S1L possesses robust ability to 
establish latency and reactivate in ex vivo cultures. However, in the presence of gB-CD8s, the 
reactivation of WT HSV was nearly abrogated, as expected from similar previous studies [68, 
78].  In contrast, reactivation of S1L was not affected by addition of gB-CD8s, as a similar 
proportion of cultures reactivated with or without gB-CD8s (Fig 9A).   However, the endogenous 
CD8+ T cells in TG that were latently infected with S1L HSV-1 were still able to inhibit S1L 
reactivation from latency as effectively as endogenous CD8+ T cells in TG latently infected with 
WT HSV-1 (Fig. 9B).  Taken together, these results indicate that S1L reactivation events do not 
appear to be recognized by gB-CD8s, but the endogenous S1L-induced CD8+ T cell response is 
equally effective as that of WT at reducing reactivation events. 
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Figure 9. Ex vivo ganglionic reactivation of WT and S1L HSV-1 
 
Corneas of B6 mice were infected with 1x105 PFU of WT or S1L HSV-1.  At 34 dpi latently infected TGs 
were dispersed with collagenase. (A) The TG cells were depleted at >95% of endogenous CD8+ T cells and 
distributed to wells of a 48-well tissue culture plate (0.2 TG equivalent/well) and cultured in culture 
medium containing IL-2 alone, or with 2 x 104 gB-CD8s added per well. Culture fluid samples were 
removed and replaced with fresh media every two days. The presence of infectious virus in culture fluid 
(indicating HSV-1 reactivation) was then determined by plaque assay. (B) TG cells were mock depleted or 
depleted of 95% of endogenous CD8+ T cells by treatment with anti-CD8α antibody and complement, then 
distributed to wells of a tissue culture plate and cultured as described in A above. (A & B) Data plotted as 
total percentage of wells that reactivated (showing infectious virus in culture supernatant) at the indicated 
time of culture. n=10 TG per condition. Data for each experiment are representative of one of two repeats, 
but experiment-to-experiment variability in reactivation rates are routinely observed. Studies completed by 
Sarah Bidula. 
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Our previous work demonstrated that the vast majority of CD8+ T cells in WT HSV-1 
acutely infected TG at 8 dpi are HSV-1 specific [77]. We considered several possible 
explanations for the compensated CD8+ T cell TG infiltrate observed here (Fig 8) in the absence 
of gB-CD8s. We assessed if a CD8+ T cell response developed to the mutated forms of the gB498-
505 epitope. B6WT3 fibroblasts were pulsed with the S1L, L8A, or WT gB498-505 peptides and co-
cultured with CD8+ T cells from TGs of S1L, L8A, or WT infected B6 mice. The ability of CD8+ 
T cells to recognize these peptides was determined by staining CD8+ T cells for intracellular 
IFNγ production (Fig 10).  Ganglionic CD8+ T cells induced by a WT HSV-1 infection 
responded robustly to stimulation with WT peptide-pulsed fibroblasts, but failed to respond to 
B6WT3 cells pulsed with S1L and L8A peptides. This suggested there is little or no cross-
recognition of the mutant peptides by gB-CD8s.  Furthermore, the compensatory ganglionic 
CD8+ T cell populations induced by HSV-1 S1L or L8A infection failed to produce IFNγ when 
stimulated with fibroblasts pulsed with any of the 3 peptides (Fig 10).  This strongly suggested 
that the compensation of the ganglionic CD8+ T cell response was not due to the development of 
CD8+ T cells directed to the mutated gB peptides. 
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Figure 10. Stimulation of acute TG-resident CD8+ T cell populations with WT, SIL, or L8A gB 
peptides 
 
B6 mice received corneal infections with HSV-1 expressing WT, S1L, or L8A gB. TG were obtained at 8 
dpi, dispersed into single cell suspensions, and the endogenous CD8+ T cells were stimulated for 6 hours 
with B6WT3 fibroblasts pulsed individually with WT, S1L, or L8A gB498-505 peptides, in the presence of 
brefeldin A. Cells were surface stained for CD45 and CD8, followed by an intracellular stain for IFNγ.  The 
data are represented as the mean percentage of CD8+ T cells that produced IFNγ +/- SEM (n=5 mice per 
group). * represents significance of p<0.0001 for each group compared to gB peptide stimulation of wild-
type infected control (first column) using one-way ANOVA with Dunnett’s multiple comparisons posttest. 
4.3 A COMPENSATORY RESPONSE TO HSV-1 SUBDOMINANT EPITOPES IN 
S1L-INFECTED TG 
We next addressed the possibility that the compensatory CD8+ T cell responses to S1L 
contained an expansion of CD8s directed to other HSV-1 epitopes. CD8+ T cells obtained from 
TG of mice infected with either WT or S1L HSV-1 were assessed both for total ganglionic CD8+ 
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T cell infiltrates (Fig 11A) and for their ability to be stimulated by infected fibroblasts at 
different times post-infection (Fig 11B and 11C).  The total ganglionic CD8+ T cell infiltrate for 
both WT and S1L showed a similar characteristic peak at 8 dpi and a subsequent contraction by 
30 dpi (Fig 11A). However, at 16 dpi S1L infected TGs had a significantly smaller CD8+ T cell 
infiltrate, suggesting a more rapid CD8+ T cell contraction occurred. 
 
Figure 11. The CD8+ T cell population in S1L infected TG contract more rapidly and contain a 
higher frequency of active non-gB-CD8s 
 
B6 mice received corneal infections with either WT or the S1L mutant at 1x105 PFU/cornea. TGs were 
harvested at 8, 12, 16, 20, or 30 dpi and: (A) stained for CD45, CD3, and CD8, analyzed by flow 
cytometry, and data recorded as the mean number of CD8+ T cells/TG; or stimulated for 6 hrs with (B) 
HSV-1 gB-null(EGFP) infected or (C) PRV-gB infected B6WT3 fibroblasts in the presence of Brefeldin A.  
The cells were then stained for surface CD45, CD3, and CD8 and for intracellular IFNγ.  Data in B and C 
are presented as the mean ± SEM frequency of IFNγ+ CD8+ T cells in each TG as a fraction of total CD8+ T 
cells.  * p<0.05, ** p<0.01, ***p<0.001 based on a t-test comparison at each time. 
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To assess the response to non-gB498-505 HSV-1 epitopes, TG from WT or S1L infected 
mice during latency were dispersed, stimulated for 6 hrs with B6WT3 fibroblasts infected with 
HSV-1 gB-null-EGFP virus, and intracellular IFNγ in CD3+CD8+ T cell populations was 
measured by flow cytometry (Fig 11B).  We found a significantly higher frequency of IFNγ+ 
CD8+ T cells in S1L-infected TG compared to WT infected TG following stimulation with UV-
irradiated B6WT3 cells infected with HSV-1 lacking gB.  At the acute stage (8 dpi), the 
frequency of S1L stimulated CD8s was approximately twice that of the WT-stimulated CD8+ T 
cells.  Intriguingly, in a WT infection, the fraction of ganglionic non-gB-CD8s responding to 
antigen drops over time. These data are consistent with our observation that in WT infected TG, 
CD8+ T cells specific for subdominant HSV-1 epitopes become functionally compromised by 30 
dpi (14). However, we found that while non-gB498-505 CD8
+ T cells in an S1L infection also 
dropped as latency was established, over 4x more non-gB-CD8s responded to infected target 
cells by producing IFNγ in this assay. This is more than can be explained by a simple doubling 
of stimulated cells to fill the gB-CD8 compartment. Rather, this observation suggests that the 
non-gB-CD8s still target HSV-1 epitopes and are more functional in TG infected with HSV-1 
S1L.  
 To separately assess CD8+ T cell responses to the gB immunodominant epitope in a 
similar assay, we stimulated CD8+ T cells obtained from S1L and WT latently infected TG for 6 
hrs with B6WT3 cells infected with a recombinant pseudorabies virus (PRV) that expresses the 
HSV gB residues 494-509 containing the HSV immunodominant peptide (SSIEFARL) under 
control of the CMV promoter (PRV-gB) and measured intracellular IFNγ (Fig. 11C).  CD8+ T 
cells in S1L infected TG responded minimally to stimulation with the PRV-gB494-509 virus 
infected cells whereas CD8+ T cells in WT HSV-1 infected TG showed a robust response that 
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was maintained throughout the establishment of latency.  These data agree with our previous 
finding that CD8+ T cells specific for the immunodominant gB498-505 epitope remain highly 
functional in TG latently infected with WT HSV-1 (14). They also demonstrate that CD8+ T cells 
in S1L-infected TG do not cross react to any presented PRV MHC-I epitopes in this assay. These 
results indicate that the compensatory response to S1L in the ganglia appears to reflect an 
increased number of CD8+ T cells directed to HSV epitopes other than gB498-505, and that these 
CD8+ T appear more functional in S1L infected TG compared to those in TG infected with WT 
HSV-1.  
4.4 EFFICIENT TG-RETENTION OF GB498-505 SPECIFIC CD8+ T CELLS 
REQUIRES ANTIGEN 
It was previously shown that activated, exogenously introduced, non-HSV-specific OT-I 
CD8+ T cells could enter the TG during acute infection, but were not retained in the TG over 
time, presumably due to lack of cognate antigen recognition within the tissue [114]. The 
availability of an HSV-1 variant lacking the immunodominant peptide allowed us to assess the 
necessity of HSV-1 antigen presence in retaining ganglionic CD8+ T cell populations in vivo. We 
performed simultaneous corneal infections with the S1L virus lacking the immunodominant 
gB498-505 epitope in conjunction with ocular or flank infections with WT virus (Fig 12A).  These 
infection models were designed to induce a systemic CD8+ T cell response to the gB498-505 
epitope and assess the retention of that response under conditions where the epitope was or was 
not expressed in the TG.  As expected, mice receiving corneal infection of either WT or S1L 
virus developed acute systemic and TG CD8+ T cell responses that contained or lacked the gB498-
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505 specific CD8
+ T cell populations, respectively (Fig 12B and 12C). When a gB498-505 specific 
CD8+ T cell response was primed in S1L ocular infected mice by coinfection with WT HSV-1, 
either in the other eye or by flank infection, we noted that the infiltrate of the S1L infected TG 
contained a CD8+ T cell response to gB498-505.  Indeed, the CD8
+ T cell infiltration of the S1L- 
and WT-infected TG were quite similar at 8 dpi, with equivalent levels of both gB-CD8s and 
non-gB-CD8s.  These data fit with the previously reported observation that acute ganglionic 
infection draws most or all activated CD8+ T cells into the ganglia [114].  However, a different 
pattern emerged by 30 dpi at HSV latency.  In WT latently infected TG, irrespective of whether 
or not they received simultaneous corneal infection with S1L virus, an approximate 50:50 
proportion of gB-CD8 to non-gB-CD8 T cells was retained during latency (Fig 12D).   However, 
in S1L latently infected mice that were co-infected with WT virus ocularly or by flank infection, 
the gB-CD8 populations were greatly reduced by 30 dpi in the S1L infected ganglia.  These 
results strongly support the conclusion that while most activated CD8+ T cell populations can 
infiltrate the ganglia at acute stages of infection, the maintenance of ganglia-resident HSV-
specific CD8+ T cell populations requires antigen expression within the TG. 
 
  52 
 
Figure 12. gB-CD8+ T cell retention in the HSV-1 latently infected ganglia is dependent on antigen 
expression 
 
(A) Representation of infection models in which mice received unilateral corneal infections with WT (WT 
only) or S1L (S1L only) HSV-1, bilateral infections with WT on one cornea and S1L on the other cornea 
(dual infection); or bilateral corneal infection with S1L and flank infection with WT HSV-1.  All corneal 
infections were with 1x105 PFU/scarified cornea, and flank infections were with 1x106 PFU on a scarified 
flank. At 8 or 30 dpi, TG and spleen suspensions were analyzed by flow cytometry for CD45, CD3, CD8, 
and gB-tetramer. (B) Total number of gB-tetramer+ cells/spleen. (C and D) Frequency of CD3+CD8+ T 
cells in the TG that are gB-tetramer+. * Statistical significance by one-way ANOVA with p<0.01. 
4.5 DEFINING THE ANTIGENIC REPERTOIRE OF THE CD8+ T CELL 
RESPONSE TO HSV S1L 
Virtually the entire CD8 antigenic repertoire to WT HSV-1 in B6 mice was recently 
defined [77]. This gave us the opportunity to examine the specific nature of the compensation to 
HSV-1 subdominant epitopes. We utilized the known HSV-1 subdominant epitope library to 
determine the size of each subdominant-epitope population that responds to peptide within the 
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TG.  HSV-1 induced CD8+ T cells infiltrating the ganglia at 8 dpi were evaluated for their ability 
to produce cytokines following stimulation with B6WT3 cells pulsed with each known epitope.  
For WT HSV-1, just over half of the CD8+ T cells in the TG of infected mice at 8 dpi responded 
to the immunodominant gB498-505 epitope, while the remaining CD8
+ T cells responded at much 
lower levels to the 19 subdominant epitopes reported previously, with the addition of one minor 
epitope that is discussed below [77].   In contrast, CD8+ T cells infiltrating S1L infected TG 
showed no reactivity to the gB498-505 epitope, but showed a statistically significant increase in 
responses to most of the tested subdominant epitopes (Fig 13A).  The response to a few 
subdominant epitopes remained statistically unaffected in the HSV S1L induced CD8+ T cell 
population, though an overall trend of increased levels was evident.   Epitopes that featured 
prominently in the altered dominance hierarchy induced by HSV-1 S1L included RR1 
(ribonucleotide reductase large subunit 1, UL39), with T cell epitope frequencies being the most 
abundant (RR1982-989) and fourth most abundant (RR1822-829) in the altered hierarchy. 
Interestingly, gB560-567 rose to position two in the hierarchy. Addition of the fractions responding 
to each peptide indicated that most of the CD8+ T cells were accounted for, with the fraction 
responding to each epitope adding to a total of 125.6 +/-33.8 percent (Fig 13B).  This strongly 
suggests that the compensation was not a result of the development of significant CD8+ T cell 
populations to new epitopes, although we cannot exclude the possibility that minor populations 
directed to previously unreported epitopes were present in HSV-1 S1L infected mice.  We also 
evaluated a subgroup of five of the specific epitopes for recognition by the HSV-1 L8A-induced 
ganglionic CD8+ T cell response, and the results suggested this virus induced a similar 
compensatory response to that of S1L (Fig 13C). Finally, it was reported by Stock, et al. (2007) 
that the systemic response to the only known epitope at that time (RR1822-829) did not expand 
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systemically; In contrast, we found that RR1982-989-specific CD8
+ T cells, defined by tetramer, 
were expanded at both acute and late times (Fig 13D).  These results indicate that the 
compensatory CD8+ T cell response to HSV-1 lacking the immunodominant gB epitope at 8 dpi 
is due to increased CD8+ T cell populations directed to the other tested subdominant epitopes.  
 
 
Figure 13. Subdominant HSV-1 epitopes expand to accommodate the loss of the immunodominant 
gB498-505 epitope during acute infiltration into the TG 
 
B6 mice received corneal infections with (A, B, D) HSV-1 WT, S1L, or (C) L8A.  TG were excised at 8 
dpi, dispersed into single cell suspensions, stimulated for 6 hrs in the presence of Brefeldin A with B6WT3 
cells pulsed with peptides corresponding to known HSV-specific CD8+ T cell epitopes, stained for surface 
CD45 CD8, and intracellular IFNγ. (A) The graph shows the percent of the total CD8+ T cell population 
staining for intracellular IFNγ by flow cytometry.  The bars represent the mean ± SEM frequency of CD8+ 
T cells producing IFNγ in response to each epitope. (B) Total fraction of gB498-505 or non-gB-CD8s 
responding to peptide stimulations as seen in (A). N = 3-8 TG equivalents per peptide. (C) A fraction of the 
peptide library was analyzed as in (A), but for the HSV-1 L8A. (D) Spleens were also excised at 8 and 20 
dpi and examined for RR1982-989 tetramer positive cells. Shown is example of tetramer staining, and a graph 
depicting the total fraction of splenic CD8+ T cells that stained positive for tetramer. A t-test was 
performed for each matched pair of responding CD8+ T cells, and * denotes p<0.05. Some studies 
completed with help from Sarah Bidula. 
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Intriguingly, a quite different pattern emerged at 30 dpi, when HSV-1 is considered to be 
latent.  The total average numbers of non-gB CD8+ T cells per latently infected ganglion that 
produce IFNγ+ in response to peptide presentation (Fig 14A). In a WT infection, the ganglionic 
CD8+ T cells to gB498-505 still responded to stimulation with peptide pulsed cells, and accounted 
for nearly half of the total CD8+ T cells detected in the ganglia (Fig 14B). However, the 
combined non-gB-CD8 populations in WT HSV-1 infected TG showed a much poorer response, 
with a total of only 27.3% of the subdominant CD8s producing IFNγ when stimulated with each 
of the subdominant peptides on B6WT3 cells.  These data fit well with earlier reports indicating 
that a significant fraction of the non-gB-CD8s in the WT latently infected ganglia are not able to 
respond efficiently to antigen[147].  In contrast, the landscape of epitopes to which S1L induced 
CD8+ T cells can respond was changed dramatically, with 3-4 epitopes rising to prominence or 
co-dominance (Fig 14A). The most prominent responses were to UL28629-637(DNA packaging 
terminase), ICP8168-176, and the two large subunit ribonucleotide reductase epitopes; RR1982-989 
and RR1822-829.  This contrasts to the sub-dominant response hierarchy against WT HSV-1, 
which changed little over time.  Secondly, when the CD8+ T cells from S1L latently infected 
ganglia that responded to peptide were totaled, 89.3 ± 16.5% of the CD8+ T cells were 
functionally able to produce IFNγ upon stimulation (Fig 14B).  This does not simply reflect 
enrichment due to the lack of a gB498-505 response since the proportion of functional non-gB498-505 
cells in this assay were significantly higher (Fig 14C). This is also in line with the data presented 
in figure 11B showing that loss of the immunodominant epitope results in a functional increase 
in non-gB-CD8s at latency. 
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Figure 14. Certain subdominant HSV-1 epitopes become more functional and arise to codominance 
in TG during HSV-1 S1L latency 
 
Studies were as detailed in Figure 13, except that TGs were harvested from infected mice at 30-33 dpi. (A) 
The order of epitopes is identical to those shown in Figure 13. For clarity, only the non-gB498-505 responses 
are shown in A, but the total percentages are displayed in (B). The bars represent the total number of CD8+ 
T cells producing IFNγ+ in response to peptide stimulation, and error bars represent SEM. For significantly 
different populations, the average fold change increase in population over wild-type is shown. (B) Total 
fraction of gB498-505 or non-gB-CD8s depicted in figure (A) that are responding to peptide stimulations. (C) 
Total fraction of the non-gB498-505 specific CD8+ T cells depicted in figure (A) that make IFNγ after peptide 
stimulation. (D) 30 dpi TGs suspensions were stained with tetramers specific to RR1-specific subdominant 
CD8+ T cell populations (tetramers for RR1 982-989 and 822-829). Shown are the total number of each 
RR1-specific CD8+ T cell population per TG. The total number of single functional (IFNγ+) or 
multifunctional (IFNγ+TNFα+CD107a+) CD8+ T cells after stimulation with a combination RR1 982-989 
and 822-829 peptides is also shown. N = 3-7 TG equivalents per group. A t-test was performed for each 
matched pair of responding CD8+ T cells, and a * denotes p<0.05. Some studies completed with help from 
Sarah Bidula. 
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Comparing the total fraction of a CD8+ T cell population present by tetramer, to that 
identified by IFNγ production after peptide stimulation should tell us what percentage of that 
specific population is functional. We could not obtain working tetramers for most CD8 
populations described here, but we were able to further characterize the functionality of RR1982-
989 and RR1822-829 CD8
+ T cell populations. This was done both by tetramer staining, and by 
determining multifunctionality (ability to produce multiple cytokines) following a peptide 
stimulation (Fig 14D). In a wild-type infected TG at latency, about 95 CD8+ T cells stained 
positive for these tetramers, with about 64% of these cells producing IFNγ, and 43% exhibiting 
multifunctionality (IFNγ+, TNFα+, and CD107a+) after stimulation. In contrast, an average of 
about 204 CD8+ T cells were tetramer positive in an S1L infected TG, with 84% capable of 
producing IFNγ, and 54% being multifunctional. This increase in functionality was statistically 
significant. Taken together, these results suggest that the presence of a strongly 
immunodominant CD8+ T cell population in latently infected ganglia adversely affects the 
functionality of those T cells reactive to subdominant epitopes.  
4.6 DISCUSSION 
Given the general propensity of CD8+ T cells to recognize only a limited and highly 
restricted array of the potential epitope repertoire of a pathogen and develop a hierarchical 
response to them, it is important to understand how the presence or absence of one epitope, 
particularly an immunodominant epitope, influences the functionality and hierarchy of the CD8+ 
T cell response to others for a specific pathogen.  Recent studies have revealed that HSV-1 
specific CD8+ T cell responses to prior HSV infections in humans are highly limited, with only 
  58 
select proteins arising to dominance or co-dominance[162]. The unusually strong 
immunodominance to gB498-505 in the B6 mouse model of HSV-1 infection and its known CD8
+ 
T cell hierarchy makes it a highly suitable and manipulatable model to address the issue of how 
loss of one epitope affects the remaining response. Previously, the nature of CD8 compensation 
for loss of immunodominance could not be more precisely defined for HSV, because the HSV-
specific CD8+ T cell repertoire in B6 has only recently been described [77]. That study 
demonstrated that the entire HSV-1 CD8+ T cell repertoire generated in the spleen was 
represented and not significantly modified in the TG, and that the vast majority of CD8+ T cells 
in the acutely infected TG at 8 dpi were HSV-specific [114]. 
Prior to this work, only one study had addressed the question of immunodominance loss 
in HSV-1, wherein B6 mouse skin infection with the HSV-1 L8A point mutation in the gB498-505 
epitope was shown to induce a normal-sized expansion of HSV-specific CD8+ T cells in the 
spleen that lacked any specificity for the immunodominant gB498-505 epitope [160].  However, the 
authors concluded that the compensation reflected an additional response to previously 
unrecognized cryptic epitopes, based largely on the observation that CD8+ T cells to the one 
known subdominant HSV-1 epitope defined at that time, RR1822-829, were not increased in 
frequency of recognition by the compensated response. This finding is similar to a study by 
Holtappels et. al with murine cytomegalovirus (MCMV), wherein they demonstrated that 
deleting two MCMV immunodominant CD8+ T cell epitopes resulted in an altered immune 
response that was still protective, but contained small changes to known subdominant CD8+ T 
cells to known epitopes, with one specific epitope identified as rising in the absence of these 
deletions [163]. Similarly, Kotturi et. al deleted several immunodominant epitopes within 
Lymphocytic Choriomeningitis virus (LCMV), and show the altered immune response contained 
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only limited increases in the subdominant CD8+ T cell hierarchy [164]. In our current study, we 
have found a somewhat different result in HSV-1 latently infected ganglia. Here we define the 
complete nature of the compensatory response in the TG and show a broad increase in the 
numbers and function of subdominant CD8 populations. Furthermore, assessment of the splenic 
response for one epitope indicates that at least part of the subdominant compensation occurs 
systemically in our model (Fig 9).  
Of the several recombinant viruses developed to lack the gB498-505 epitope, two retained 
WT levels of pathogenicity in the mouse model. We chose S1L for most of the detailed studies, 
since L8A trended toward a marginally reduced ganglionic infiltrate in the TG (Fig 4) although 
differences were not significant [160].  Reduced virus replication in the eye or TG may affect the 
level of antigen available for CD8+ T cell priming, recruitment and/or retention, as has been 
observed in the LCMV model [165]. S1L not only established latency with the same genomic 
loads as WT HSV-1, but also reactivated to the same efficiency in the absence of T cells.  Both 
S1L and L8A viruses induced total ganglionic CD8+ T cell responses numerically identical to 
WT, despite the fact that the ~50% gB498-505 specific response was absent.  Importantly, we show 
that neither S1L nor L8A virus induced a CD8+ T cell response to the native or mutated gB498-505 
epitope, as demonstrated by priming and peptide stimulation assays (Fig 6).  The lack of 
response to the S1L modified gB498-505 epitope was also established by demonstrating that (i) 
CD8+ T cells from mice infected with WT HSV failed to respond to the S1L modified gB 
protein: (ii) CD8+ T cells in TG harboring the S1L virus showed negligible binding to tetramers 
containing the native gB498-505 epitope; and (iii) gB498-505-specific CD8
+ T cells that effectively 
prevented reactivation of the parental wild-type HSV-1 strain had no effect in reducing 
reactivation of S1L from latently infected TG in ex vivo cultures.  The epitope-specific nature of 
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the reactivation blockade by gB-CD8s (Fig. 5) also provides strong evidence that MHC-I 
presentation and cognate CD8+ T cell recognition are absolutely required to stop viral exit from 
latency in this model. This is consistent with our previous finding that HSV-1 specific CD8+ T 
cells from C57BL/6 mice can block HSV-1 reactivation in latently infected TG of C57BL/6, but 
not BALB/c mice [68], and contrary to a recent study suggesting that CD8+ T cells do not control 
HSV-1 reactivation events[166]. 
The nature of the compensatory CD8+ T cell response in the acute infected TG to an 
immunodominant epitope-mutated HSV-1 reported here appears to be predominantly or entirely 
due to CD8s specific to other HSV-1 epitopes (Fig 7B).  The compensatory increase of 
subdominant CD8+ T cell responses to epitope deleted viruses has been seen in other viruses, for 
example, following infection with an influenza virus that lacked an immunodominant epitope 
[167]. However, CD8+ T cell compensation was not observed following infection with epitope 
deleted LCMV, where the CD8+ T cell response was both numerically reduced and delayed [168, 
169].  As noted by Stock et al [160] it is not clear if this difference in the ability to compensate 
for the loss of an immunodominant epitope reflects the difference between a local infection, like 
influenza and HSV-1, and a systemic infection like LCMV.  Our studies using B6WT3 cells 
pulsed with each of the 19 known subdominant CD8+ T cell epitopes to stimulate IFNγ 
expression in CD8+ T cells indicate that most subdominant CD8 populations increased in size to 
compensate for the loss of an immunodominant epitope. The added total CD8+ T cell response 
accounts for all (125.6% ± 33.8%) CD8+ T cells in S1L acutely infected TG, not only confirming 
that they are still HSV-1 specific, but suggesting negligible induction of CD8+ T cells specific 
for new cryptic HSV-1 epitopes. One possible exception to this is UL25338-345, which was a low 
frequency epitope identified, but not reported, in our previous study[77]. This CD8+ T cell 
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population was identified as a small response (~0.2% of the total) in WT HSV-1 infections in our 
initial screen, but not in the subsequent repeat, suggesting a possible low frequency response in 
WT HSV-1. In an S1L infection, however, this epitope represented ~4% of the total acute TG 
infiltrate. We interpret this finding as an expansion of an existing low-frequency epitope-specific 
CD8+ T cell response. While we cannot exclude the possibility that S1L induced additional CD8+ 
T cell populations arising to new or cryptic epitopes, these would necessarily be small 
populations that would be difficult to identify via peptide library screening. 
The change in the acute dominance hierarchy in the absence of the immunodominant 
gB498-505 epitope was not predictable. Compared to WT, the frequency of acute CD8
+ T cells in 
the TG reactive to some epitopes such as UL39982-989 increased 4-fold, while the response to 
others such as UL29876-883 were only modestly increased. The response to others such as US44-12 
showed little change compared to WT. However, 14 of the 19 subdominant CD8+ T cell 
populations in the S1L infected ganglia showed a significant increase (Fig 9).  The reason for 
this differential rise of epitope-specific CD8+ T cell responses in the absence of the 
immunodominant epitope is not clear.  Priming of the initial CD8+ T cell hierarchy as well as 
expansion of memory subsets are very dependent on the context of naïve T-cell-APC 
interactions, and T cells directly compete for antigen on APCs very early in this process[170-
172].  CD8+ T cell population hierarchies also depend on naïve precursor frequency as well as 
peptide processing and MHC binding strength[164]. Selection in our model is not completely 
attributable to MHC binding capacity, since epitopes that changed little in the dominance 
hierarchy such as UL29876-883 and UL4083-90 were previously reported [77] to have higher MHC-
binding capacity (IC50 = 6.2 nM and 5.4 nM, respectively). Epitopes such as gB560 that rose 
substantially in the S1L dominance hierarchy had a much lower MHC binding capacity (IC50 = 
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9206 nM). The naïve precursor frequencies for the full HSV-specific response in our model have 
not yet been fully explored, but are outside the scope of this study. The kinetics of viral protein 
production are also likely to influence CD8+ T cell hierarchy, since a majority (~80%) of the 
epitopes recognized by CD8+ T cells in B6 mice are encoded by viral early (β) and leaky late 
(γ1) genes.  This would be consistent with our previous finding that expressing gB as a true late 
(γ2) gene greatly reduced gB498-505 immunodominance [153]. Other studies using MCMV, 
Vaccinia, and Epstein-Barr epitopes also suggest that the context and kinetics of viral antigen 
expression contribute heavily to CD8 immunodominance, with the trend of stronger and earlier 
expression and presentation being important for the development of immunodominant CD8 
populations[173-176]. However, we note differential rise to dominance of epitopes on the same 
viral protein in TG infected with S1L, suggesting that the level of expression of a particular viral 
gene product cannot by itself explain changes in immunodominance. 
In the LCMV model it has been observed that when the virus is cleared acutely, the 
lasting memory CD8+ T cell hierarchy is maintained at similar proportions, but when a chronic 
strain is used, the hierarchy changes over time[177]. It is thus intriguing that the hierarchy at 
latency in the S1L-infected TG is quite different from the hierarchy at acute infection. With our 
dual eye infection or flank infection models, we show that gB-CD8s are not retained in TG 
latently infected with the S1L virus that lacks this epitope (Fig 8), agreeing with previously 
published data demonstrating that antigen is necessary to effectively maintain exogenously 
added memory CD8+ T cells in nonlymphoid tissues[136, 178]. Thus, differential expression of 
viral proteins or peptides during contraction/latency appears to be one among a complex set of 
mechanisms that define the CD8+ TCR repertoire in latently infected TG.  This indicates a 
requirement for ongoing antigen detection to maintain memory CD8+ T cells in TG during 
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latency, and also implied ongoing recognition by non-gB-CD8s in the TG of latently S1L-
infected mice during latency.  Various levels of antigen recognition during the contraction phase 
may also explain the faster CD8+ T cell contraction observed in the S1L infected TG at 16 dpi 
(Fig 7A). Although the pool of possible ganglionic memory CD8+ T cells is shaped early in the 
lymphoid tissue, it is likely that competition for antigen recognition is a major factor responsible 
for determining which CD8+ T cell populations are retained efficiently and which subsequently 
arise to prominence in latently infected TG.  
We present several lines of evidence to suggest that the subdominant CD8+ T cells in the 
S1L latently infected TG are more functional than those in the WT HSV-1 latently infected TGs. 
Specifically, in stimulations with gB-null HSV-1 infected cells, the fraction of responding CD8s 
in TG latently infected with S1L was four-fold higher than the fraction of responding cells in TG 
infected with WT virus (Fig 7B). This was considerably more than that expected from a simple 
doubling of numbers due to the compensatory response for loss of the gB-CD8s. In addition, the 
total number of all CD8+ T cells responding to peptide stimulation in S1L latently infected TG 
was approximately twice that of the fraction of subdominant CD8s responding in a WT latent 
infection (Fig 10B). Indeed, the response seemed to account for most of the CD8+ T cells in 
those S1L latently infected TG. Finally, measuring of two major subdominant populations 
directed to RR1 by parallel tetramer staining and analysis in response to peptide stimulation 
indicated that proportionally more of these RR1-specific cells show multifunctionality than do 
those same T cells from a WT latent infection (Fig 10C). Taken together, these data suggest that 
eliminating the strongly immunodominant gB498-505 epitope increases the function of remaining 
CD8+ T cells specific for some non-gB498-505 HSV-1 epitopes.  
  64 
We previously demonstrated that i) subdominant CD8+ T cells have a higher frequency 
and express higher levels of PD-1 and show less apoptosis when PD-1 ligation is blocked within 
latently infected TG [148]; and ii) in vivo IL-10R blockade significantly increased the number, 
but not the frequency of subdominant CD8+ T cells in TG latently infected with WT HSV-1, and 
increased their ability to block HSV-1 reactivation from latency in ex vivo TG cultures[147]. 
These characteristics are consistent with an exhausted phenotype. Here and in previous studies 
[147, 148] we show that TG that are latently infected with WT virus contain functionally 
exhausted subdominant CD8s, but near fully functional immunodominant gB-CD8s.  Thus, in 
TG latently infected with WT HSV-1 the frequency of cytokine producing cells following 
peptide stimulation was similar to the frequency of the corresponding tetramer positive cells in 
the immunodominant population, but significantly lower in subdominant populations.  Using the 
same analysis, we now show significantly reduced functional exhaustion of the subdominant 
CD8+ T cells in TG that lack the gB498-505 immunodominance.  We further demonstrate a 
significantly increased number of multifunctional subdominant CD8+ T cells in TG latently 
infected with HSV-1 lacking the immunodominant epitope when compared to those infected 
with WT HSV-1.  
It is unclear why i) subdominant CD8+ T cells become partially exhausted in latently 
infected TG while immunodominant gB498-505-specific CD8
+ T cells retain nearly full 
functionality; and ii) subdominant CD8+ T cells show less functional exhaustion in latently 
infected TG that lack the immunodominant population.  Given the recent evidence demonstrating 
the unregulated nature of antigen expression in periods of phase 1 “animation” during 
latency[66], effective CD8+ T cell surveillance of a variety of viral targets may provide better 
monitoring of neurons in the early stages of reactivation. There is likely an interplay between the 
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amount of leaky viral antigen presentation during latency and the number of specific CD8+ T 
cells that can possibly “see” that antigen. However, this interplay may also explain the 
phenomena observed here- wherein there exist an apparently very low frequency of latently 
infected neurons that express viral proteins[67]. The absence of the gB498-505-specific responses 
by immunodominant T cells may itself influence sporadic antigen expression during latency in 
the TG, which may change how other T cells see such expression in general.  This may in turn 
affect the function of the subdominant T cells.  Furthermore, in TG infected with WT HSV-1, the 
frequency of gB498-505-specific CD8
+ T cells is high, reducing the likelihood of any one cell 
receiving the multiple exposures to cognate antigen required for functional exhaustion over time.  
In contrast, the frequency of subdominant CD8+ T cell populations is low, increasing the 
likelihood of such repeat encounters with cognate antigen.  In TG harboring latent S1L virus, the 
subdominant populations are greatly expanded, which should alter the dynamics and reduce the 
likelihood of repeat antigenic exposure.  As such, the mechanisms underlying the functional 
differences may be very complex and multifactorial. 
In summary, we have precisely defined the nature of a compensatory subdominant T cell 
response infiltrating the TG, a site of HSV-1 latency in our model, and show that it is due to 
expansion of the non-gB-CD8 populations. However, during latency, this population adopts a 
state where there are multiple CD8+ T cell populations that rise to co-dominance, in part due to 
ongoing antigen expression within the TG during contraction. Furthermore, at latency these 
CD8s demonstrate an increased functionality compared to their WT-induced counterparts. This 
results in a broader repertoire of functional HSV-specific CD8+ T cells, which should increase 
the set of antigenic targets that can be used by CD8+ T cells to prevent HSV-1 reactivation from 
latency. 
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5.0  ALTERING PROMOTERS THAT DRIVE AN IMMUNODOMINANT HSV-1 
EPITOPE INFLUENCES CD8+ T CELL PRIMING, DEVELOPMENT, AND 
GANGLIONIC RETENTION AT LATENCY 
Multiple factors influence the antigen hierarchy, function and breath of the CD8+ T cell 
response to a specific pathogen. These include precursor frequency of T cells to a specific 
antigen, the level and chronicity of protein expression and the presentation of antigens to the 
developing T cells in the lymphoid organs in the priming process[164, 170-172].  For HSV, it is 
remarkable that the gB498-505 epitope is so powerfully immunodominant and the important factors 
governing this are not clear.  To investigate such factors, we recently detailed a study of the 
CD8+ T cell response to a recombinant virus in which expression kinetics of gB were altered to 
γ2 kinetics [153].  Indeed, this virus primed an effective immunodominant gB-CD8 response, but 
there were considerably less gB498-505 specific CD8
+ T cells retained in the ganglia throughout 
latency, compared to the response directed to a wild-type HSV[153].  The data suggested that 
delaying the expression of gB results in reduced antigenic exposure during latency and less 
ganglionic retention of gB-CD8s. However, interpretation of these results was complicated by a 
growth impairment of the virus, most likely as a result of the elimination of some roles of gB 
early in infection.  We therefore decided that a thorough analysis of the contribution of viral 
promoters and different kinetics of expression on CD8+ T cell populations was further warranted.   
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Here, we evaluate the contributions of different viral promoters by exploiting a recently 
described recombinant HSV-1 in which the native gB498-505  epitope is not present, but gB is 
expressed normally and appears to maintain its functions[155].  This was used to derive 
recombinant viruses in which the missing epitope was expressed at an ectopic site under the 
control of several different promoters.  Thus, the immunodominant gB498-505 epitope expression 
profile could be altered independently of the essential and important gB protein.  It allowed us to 
address two questions: (1) can the immunodominance of the CD8+ T cell population to gB498-505 
be increased by increasing expression of this epitope, or by expressing it from more active or 
earlier expressed viral promoters? and (2) does epitope expression from candidate late promoters 
alter the development of the CD8+ T cell response and ganglionic retention?  Establishing the 
requirements for efficiently eliciting and maintaining an effective CD8+ T cell population 
throughout latency is vital for maintaining HSV-1 in its latent state.  Here, we show that 
changing epitope expression does not appear to increase the immunodominant fraction of CD8+ 
T cells beyond the WT levels of ~50%, but expression from different late promoters can 
influence overall CD8+ T cell priming, ganglionic infiltration and retention of CD8+ T cell 
populations associated with HSV -1 latency.  
 
5.1 ECTOPIC EXPRESSION OF THE GB498-505 PEPTIDE RESTORES A STRONG 
GB-CD8 T CELL RESPONSE  
The goal of these studies was to determine how the activity of different constitutive, 
early, late and latency-active promoters influence the numerical and functional gB-CD8 response 
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in the HSV latently infected ganglia.  We aimed to determine if the fraction of immunodominant 
gB-CD8s in the ganglionic CD8+ T cell population could be increased by using promoters that 
mediate greater long-term expression.  We were also interested in further evaluating how true-
late γ2 promoters affect the hierarchy, since our previous data had suggested that γ2 promoter 
activity was poor at retaining gB-CD8 populations within the ganglia[153]. Finally, we aimed to 
determine if the promoter of LAT could be used to enhance the infiltrate.  Given that HSV gB 
(containing the immunodominant gB498-505 epitope) has multiple essential roles at several stages 
of HSV infection, we considered it unwise to adopt the same strategy, where expression of the 
complete gB was altered.  Indeed, we found that altering the kinetics of gB expression to a true 
late gene had a fitness cost to the virus[153].  We therefore aimed to separate the peptide from 
the gB protein using a recently detailed recombinant HSV-1 that contains a single point mutation 
(S1L) in the gB498-505 epitope that eliminates the priming and development of gB498-505 specific 
CD8+ T cells in B6 mice, but does not appear to alter virus fitness[155].  The S1L virus appears 
to be as pathogenically fit as wild type, generates an equivalent sized CD8+ T cell response in the 
ganglia as seen with wild type virus, but gB-CD8s are not primed. Rather CD8+ T cells to 
subdominant HSV-1 epitopes expand to fill the absent gB-CD8 T cell compartment[155].  In this 
background, we derived a recombinant HSV-1 that expressed a 4-mer of the gB494-509 peptide as 
a GFP fusion protein, all under sequences containing the gB promoter (gBp), and placed at the 
gC locus (Fig 15A).  Recombinant HSV-1 with insertions disrupting the expression of gC are not 
pathogenically impaired, compared to wild type HSV-1 KOS, in the corneal scarification B6 
model[179].  When mice were infected by the ocular route with recombinant virus expressing the 
epitope ectopically (HSV gBp), we found an efficient generation of HSV-1 specific CD8+ T cell 
responses in the TG-infiltrating population that contained gB498-505 specific CD8s, detected using 
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gB498-505 H2K
b MHC-I tetramers, at 46.7%, a level not significantly different from that seen for 
WT HSV infected mice (Fig 15B).  Thus, we can effectively separate expression of the 
SSIEFARL epitope from gB protein. This allows us to manipulate this epitope’s expression 
without affecting essential protein gB, with both the kinetics of expression and its function in 
infection unaffected in our subsequent recombinant viruses.   
 
Figure 15. Ectopic restoration of gB498-505 specific CD8+ T cell response in S1L parental strain under 
gB promoter 
 
A) Depiction of ectopically restored gB peptide expressing virus. In a gB-S1L point mutation parental 
strain, the native gC promoter drives a monomeric red fluorescent protein (mRed, mRFP), followed by an 
inserted gB promoter and gB494-509 4x repeat linked to EGFP. B) B6 mice infected at 1x105 PFU/eye with 
either S1L parental strain or the ectopically restored gBp virus.   At 8 days post infection, TGs were 
removed and single cell suspensions obtained as described in materials and methods. Resulting cell 
suspensions were stained with αCD45, CD3, CD8, and gB498-505 tetramer. Depiction is representative of one 
of five similar results for each group, with flow cytometric analysis of gB498-505 tetramer staining of the total 
ganglionic CD45+CD3+CD8+ T cells shown. 
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5.2 EXPRESSION KINETICS OF THE GB498-505 EPITOPE FROM DIFFERENT 
PROMOTERS IN RECOMBINANT HSV-1 
Since we can restore the gB response with ectopic peptide expression, we used the same 
strategy to develop recombinant HSV-1 with different promoters driving expression of the gB498-
505 epitope. One goal was to determine if constitutive or potentially more active promoters might 
be capable of driving an even higher skewing of the CD8+ T cell response to the gB epitope, over 
that made by the gB promoter in the wild-type virus.  The constitutive CMV immediate early 
promoter (CMVp) and ICP0 immediate early promoter (ICP0p) were evaluated because they are 
known to be efficiently expressed during a viral lytic infection and the CMV IE promoter may be 
active during latency.  We also evaluated the VP16 promoter (VP16p), which is expressed in a 
lytic infection with leaky-late or γ1 kinetics, like the gB protein.  Intriguingly, recent work 
suggests that VP16 is controlled in ganglia as a “phase 1” gene, expressed before α genes in the 
context of murine HSV reactivation from latency [180].  We also evaluated three true late γ2 
promoters to build on our previous studies[153], but without the complication of a considerably 
less fit virus background (from the gC, UL38, and UL41 genes; HSV-gCp, UL38p, and UL41p 
respectively). UL41 has been suggested to be expressed especially late in the infectious cycle, 
based on transcription analyses, with little to no transcript detectable 2 hours post infection[181].  
Finally, we examined virus in which gB epitope was expressed from the full latency active 
promoter (LAP) which is responsible for abundant expression of LAT transcripts in neurons 
during latency[182-184]. 
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Table 2. Promoters chosen for ectopic gB498-505 peptide expression 
Promoter Description Forward Primer 5’-3’ Reverse Primer 5’-3’ 
gBp HSV-1 γ1 late 
promoter for 
glycoprotein B 
GGATCCGGATCCGC 
ACGACGGGCCCCCG 
TAG 
AAGCTTAAGCTTTA 
ATACAGCGCGGTGT 
TGG 
CMVp CMV α promoter, 
constitutive expression 
GGATCCGGATCCCT 
GAGTCCGGTAGCGC 
TAGCGGATCTGACG 
GTTCACTAAA 
AAGCTTAAGCTTTAG 
TTATTAATAGTAATC 
AATT 
ICP0p HSV-1 α promoter for 
ICP0 
GGATCCGGATCCGG 
GTCGTATGCGGCTG 
GAG 
AAGCTTAAGCTTACTT 
GCAAGAGGCTTTGTTC 
VP16p HSV-1 γ1 late 
promoter for the VP16 
transactivator 
GGATCCGGATCCGG 
TTGATACGGGAAAG 
ACGATATC 
AAGCTTAAGCTTCACG 
GCGACTCGAGGGCGT 
TC 
gCp HSV-1 γ2 late 
promoter for 
glycoprotein C 
Native promoter region Detailed in methods 
UL38p HSV-1 γ2 late 
promoter for UL38 
capsid protein 
GGATCCGGATCCTG 
GTCTTCATTGCGAC 
CAC 
AAGCTTAAGCTTTGCC 
GTCTCGGCCGTGGG 
UL41p HSV-1 γ2 late 
promoter for UL41, 
Virion host shutoff 
gene 
GGATCCGGATCCGA 
TGTCAGGTCAATTG 
TAA 
 
AAGCTTAAGCTTCGG 
CGCCCTGCAGGACCAC 
LAP Full 2kb HSV-1 
LAP1/2 promoter for 
LAT 
Fragment generated by 
restriction digestion 
Detailed in methods 
 
All recombinant HSV-1 in this study contained the epitope expression cassette at the gC 
locus and were derived using classical homologous recombination. Expression of red fluorescent 
proteins from the gC locus was used to plaque purify virus to homogenous recombinant stocks.  
Infectious virus was gradient purified for all subsequent studies. A fitness study of each 
recombinant virus using a single-step growth curve in Vero cells showed no significant 
differences in growth, compared to both the KOS parental strain (Fig 16) and the HSV-1 S1L 
parental virus. 
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Figure 16. Growth curve of recombinant viruses 
 
5*10^5 Vero cells were infected at an MOI of 1. An initial 0 hour timepoint is the inoculum, with 2, 4, 
8, 12, 18, and 24 hour timepoints taken, freeze-thawed 3x, and virus concentration determined by 
plaque assay on Vero monolayers. 
 
We next sought to establish if the gB-epitope peptide was expressed from these viruses as 
expected.  While the strategy was designed yield viruses that express the gB peptides as GFP 
fusions, we did not see GFP signals in the appropriate channels by fluorescence microscopy, and 
immunoblot analyses for GFP protein in recombinant virus-infected cell extracts showed little 
protein of the expected size (data not shown).  We suspected that the peptide-GFP protein was 
unstable, but reasoned that increased proteosomal degradation may permit rapid surface MHC-I 
presentation of peptide to CD8+ T cells.  Peptide expression was thus evaluated using a modified 
gB-CD8 T cell stimulation assay, previously used to show the very early (<2 hrs) expression of 
gB in a lytic HSV infection[185].  Monolayers of the MHC-I compatible B6 mouse-derived 
fibroblast cell line, B6WT3, were infected with each virus and infections halted at 4, 8 and 24 
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hpi by a pre-calibrated exposure to 254nm UV light under sterile conditions.  Cells were then 
cocultured with 1 x 105 splenic gB-CD8+ T cells/culture derived from the spleen of 8 dpi HSV-
infected gB-T mice (Fig 17A).  The gB-T1 mice are transgenic for a gB498-505 specific T cell 
receptor, so that the vast majority of activated CD8+ T cells recognize the gB498-505 epitope [156]. 
Coculture in the presence of Brefeldin A allowed intracellular cytokine accumulation of TNFα 
and IFNγ for immunodetection and flow cytometry quantification in cells gated for CD45, CD3 
and CD8 (Fig 17B). 
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Figure 17. Viral expression of gB498-505 from selected promoters is detected by gB495-505 specific CD8+ T 
cells 
 
(A) Depiction of experimental setup.  Confluent 12-wells of B6WT3 cells were infected with 
approximately 1x106 PFU at an MOI of 1 with WT HSV-1, S1L, or each promoter virus. At 4, 8, or 24 
hours each plate was UV-inactivated (with less than 10 PFU remaining per well), and combined into 
coculture with 1x105 splenic cells derived from an 8 dpi infected gB-T mouse for 6-8 hours in the presence 
of Brefeldin A. Cocultures were then stained for CD45, CD8, IFNγ and TNFα. (B) Flow cytometry controls 
including isotype antibodies for IFNγ and TNFα, a PMA/Ionomycin positive control, and an uninfected 
B6WT3 fibroblast negative control. (C) Representative flow cytometric analysis from each group of 
intracellular staining for IFNγ and TNFα. D) Quantitation of data representative of five experiments, with 
the total number of IFNγ+ CD8+ T cells per coculture stimulation shown. 
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In summary, each promoter-recombinant HSV-1 stimulated gB498-505-specific CD8
+ T 
cell responded in a manner consistent with the promoter chosen.  A small number of gB-CD8s 
recognized wild-type HSV -1 KOS infected B6WT3 fibroblasts at 4 hpi, with numbers 
increasing to 24 hours, consistent with the leaky-late expression kinetics expected for gBp.  In 
contrast, cells infected with HSV S1L, the parental virus lacking the gB498-505 epitope, did not 
elicit any detectable cytokine production in gB498-505-specific CD8
+ T cells, establishing the 
specificity of the assay and showing that cytokine-positive CD8+ T cells were a specific response 
to MHC-I presented gB498-505 peptide.  Similar timing and kinetics of gB-CD8 activation were 
seen with cells infected by HSV-gBp, compared to wild-type HSV KOS, although they were 
consistently higher in number at every timepoint analyzed.  This was not unexpected, because 
the peptide cassette expressed in these studies was a 4-mer repeat of gB494-509 linked to GFP.  
Recombinant HSV with peptide driven by the constitutive CMV IE promoter and the ICP0 
promoter activated gB-CD8s considerably more efficiently at 4 hrs, and to much higher levels 
than seen from the gB promoter at 4 and 8 hpi, as might be expected from immediate early 
expression programs following initiation of infection.  The gB-CD8s also responded at high 
levels to cells infected with HSV expressing the epitope under the VP16p, with relative levels 
similar to that expressed from the gB promoter at each time point. Again, many more activated 
gB-CD8s developed intracellular cytokine expression than that seen in parallel wild-type HSV 
infected cells at each timepoint.  In contrast, expression from the true late promoters gCp, 38p, 
and 41p resulted in only low levels of recognition at 4 hrs, but by 24 hr post-infection, the levels 
of activated CD8+ T cells were similar (38p) or higher (gCp) than those of wild-type HSV-1 
KOS at the same time point. This was consistent with expected true-late gene expression 
kinetics.  Only the LAP showed a weaker activation of T cells than wild type infections by 24 
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hpi. (Fig 17C).  This would be consistent with previously published data indicating LAP activity 
in lytic infections expresses with true-late gene kinetics, but only at low levels [182, 186].  
5.3 CD8+ T CELL RESPONSES IN MICE INFECTED WITH HSV EXPRESSING 
GB498-505 FROM DIFFERENT PROMOTERS 
The panel of recombinant HSV-1 promoter-peptide viruses were next evaluated for in 
vivo fitness by measuring their ability to both reach the murine TG after ocular infection and to 
induce a ganglionic CD8+ T cell response at the onset of latency. Parental S1L virus was 
previously shown to induce a ganglionic viral load at day 8 at levels similar to that for mice 
infected with HSV-1 KOS, and to also induce an equivalent sized ganglionic CD8+ T cell 
infiltrate[155].  Corneas of B6 mice were infected with 1x105 PFU of HSV-1, the S1L mutant, or 
each promoter virus. Ganglionic loads were determined using qPCR real time methods at 8 dpi 
using a well characterized primer set recognizing sequences in gH [153].  As expected, S1L and 
KOS viral DNA loads in the ganglia at day 8 were similar.  All the new recombinant HSV 
generated from S1L yielded a ganglionic DNA load at least as robust as wild type HSV S1L, 
indicating that they were sufficiently robust to establish latent genome loads at least as efficiently 
as the parent S1L and wild type HSV (Fig 18).  When T cells were assessed, the total number of 
CD8+ T cells infiltrating the ganglia at the peak infiltrate time of 8 dpi (Fig 19A) and the 
contracted infiltrates at latency (day 30-35) were similar to those induced by wild type HSV-1 
(Fig 19B). We previously observed that significantly attenuated viruses do not induce large 
CD8+ T cell infiltrates (unpublished data). We take these data to indicate that recombinant 
viruses used in this study were not significantly attenuated in either establishing latency, or 
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generating the peak ganglionic CD8+ T cell infiltrate that are retained after contraction and 
throughout latency.   
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Figure 18. Ganglionic viral genome copy number in C57Bl/6 mice 
Genome copy number determined by qPCR in the TG of mice ocularly infected with 1x10^5 PFU of HSV-
1 WT, S1L, or gB498-505 promoter-viruses following harvest at day 8 post infection (n=4-10 per group). 
Values are representative of the total copies per 100ng of TG DNA recovered. No significant differences 
from WT. HSV-1 BAC standards used as a positive control for detection, as well as calculations for viral 
copy number. 
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Figure 19. gB498-505 specific CD8+ T cell responses to selected gB498-505 promoter viruses 
 
Corneas of mice were infected with 1x105 PFU/eye of HSV-1 WT, S1L, or a recombinant HSV-1 
expressing gB498-505 from the indicated promoter.  At 8 dpi (peak CD8+ T cell infiltrate) or 30 dpi (latency), 
TG and spleen were dissociated into single cell suspensions and surface stained with antibodies to CD45, 
CD3, CD8, and with MHC-I gB498-505 tetramer as detailed in Methods.  Cells were subsequently analyzed 
by flow cytometry and show total CD8+ T cells per TG at (A) 8 dpi. or (B) 30 dpi. (C) The total number of 
gB498-505 tetramer positive CD8+ T cells in each spleen at 8 dpi. are also shown. (D) The fraction of gB498-505 
tetramer positive cells among the total CD8+ T cells in the TG at day 30 is shown.   
 
 
One aspect of these that viruses differed was their induction of the gB-CD8 compartment, 
which was quantified using gB498-505 specific tetramers to identify gB-CD8s (Fig 19C, D).  
Quantifying the priming by splenic gB-CD8 T cell levels revealed that five of the viruses 
(CMVp, gBp, ICP0p, VP16p and gCp) primed strong gB-specific responses, although levels in 
the spleen differed somewhat from virus to virus.  Surprisingly, three viruses induced very few 
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splenic gB specific CD8 T cells by day 8, suggesting a lack of gB-CD8 T cell priming.  In the 
infected TG at 8 days, when HSV begins to enter latency, viruses that primed gB splenic CD8+ T 
cell responses showed remarkably similar fractions of the ganglionic infiltrate to be gB498-505 
specific- in all cases representing more than 40% of the CD8s in the ganglia.  This is within the 
range of that induced by wild type HSV-1 infections.  One exception was HSV-1 gCp, where 
few gB-CD8s were seen at day 8, despite an apparent systemic priming.  Not surprisingly, gB-
CD8s were not detectable in ganglia latently infected with viruses that failed to prime an early 
gB-specific CD8 response.   
Examination of the contracted and retained CD8+ T cell infiltrate at latency indicated that 
the above viruses could be divided into one of two groups: those that developed an 
immunodominant gB-CD8 response, and those that did not (Fig 19D). Viruses that effectively 
primed a gB498-505 specific CD8
+ T cell response, including HSV-gCp, developed a ganglionic 
infiltrate that was typically dominated by gB-CD8s at levels seen in mice infected with wild type 
HSV-1.  Given that these ectopic peptide-promoter viruses expressed higher numbers of gB498-505 
epitopes than wild type as measured by T cell activation (Fig 17), this strongly suggests that 
neither higher epitope expression levels nor earlier expression in the context of a lytic HSV 
infection results in a higher proportional gB-CD8 response in the ganglia.  This result suggests 
that the differential expression from stronger promoters is unlikely to increase the gB-CD8 T cell 
fraction in the ganglionic population at latency. The second group of viruses (38p, 41p, LAP), 
which primed few to no ganglionic gB-CD8s, showed comparatively very little to no gB-CD8 
infiltration in the latently infected ganglia.  However, these are further analyzed in studies 
described below.  
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We next addressed functionality of the gB-CD8 and non-gB-CD8s in the TG at latency 
for the five viruses in which a gB-CD8 response was primed.  Previous work indicated that a 
wild-type HSV infection results in development of ganglionic gB-specific CD8s of high 
functionality from onset through HSV-1 latency, even up to 90 days post infection[68, 147]. 
However, non-gB-CD8 populations develop signs of functional exhaustion and express less 
granzyme B and significantly more of the exhaustion marker PD-1 on their cell surface.  We 
hypothesized that the different expression kinetics from the various promoters may result in 
changed levels of functional phenotype markers for the gB-CD8 and non-gB-CD8 populations.  
One factor influencing CD8+ T cell functionality is the chronicity of antigen expression during 
viral persistence [187].  We therefore examined long-term latent infections of each virus for the 
phenotype of ganglionic CD8+ T cells, using surface expression of the exhaustion marker PD-1 
and intracellular staining for the functional marker granzyme B.  By 90 days post-ocular 
infection, all viruses maintained an immunodominant gB-CD8 infiltrate, accounting for 50% 
CD8+ T cells (Fig 20A).  Wild type HSV-1 gB-CD8s showed only very low levels of surface 
PD-1, while non-gB-CD8s showed considerably more with surface PD-1 expression, reaching 
average levels more than 21% (Fig 20B).  A reverse correlation was seen for granzyme B, in that 
most gB-CD8s stained positive for granzyme B, while less than 20% of the non-gB-CD8s were 
granzyme B positive (Fig 20C).  When examining the infiltrates to the different promoter-epitope 
viruses, there was overall a similar phenotype to that seen for wild-type, in that gB-CD8s showed 
high functionality and low PD-1, while non-gB-CD8s were consistently higher in PD-1 levels 
compared to gB-CD8s. Subtle differences were apparent; the fraction of granzyme B positive 
gB-CD8s were highest for wild type and the HSV-1 gBp viruses and trended lower in ganglionic 
gB-CD8s for all other promoter viruses.  Again, all viruses induced higher levels of PD-1 on 
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non-gB-CD8s than the gB-CD8s.  We take these results to indicate that the different promoters 
do not greatly affect the proportion of gB-CD8 vs. non-gB-CD8 T cells that are functional, and 
for all viruses, CD8+ T cells that recognize the gB epitope retain a more functional phenotype 
than the non-gB-CD8s.   
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Figure 20. gB-specific CD8+ T cells remain more activated during long-term latency than 
subdominant ones 
 
Corneas of mice were infected with 1x105 PFU/eye of HSV-1 WT KOS, gBp, CMVp, ICP0p, VP16p, or 
gCp.  At long-term latency timepoint, 90 dpi. TG were dissociated into single cell suspensions and surface 
stained with antibodies to CD45, CD3, CD8, PD-1, and MHC-I gB498-505 tetramer, and stained 
intracellularly for GzB, as detailed in Methods. Cells were analyzed by flow cytometry, and the data are 
presented as the mean +/- SEM (n=5-10 mice per group [10-20 TGs per group]) of (A) percentage gB-
tetramer+ of total CD8+ T cells per TG. The percent of gB498-505 tetramer positive (gBs) or negative (gB-
nons) CD8+ T cells in each TG that are (B) PD-1 or (C) GzB positive are also shown. The data shown is 
representative of two separate experiments. * denotes p<0.05, ** denotes p<.01, by one-way ANOVA with 
multiple comparisons. 
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5.4 EPITOPE EXPRESSION FROM CANDIDATE TRUE LATE PROMOTERS 
RESULTS IN POOR GB-CD8 PRIMING 
Additional studies were undertaken with HSV expressing epitope from gCp. Infection 
with this virus clearly primed a systemic gB-CD8 response, but few gB-CD8s infiltrated the 
ganglia at day 8, while a typical half fraction of total CD8s at day 30 latency were gB498-505 
specific (Fig 21A).  When the ganglionic infiltrate began to contract from day 10 onwards, the 
fraction of CD8s specific for gB increased, and by day 12, it reached the level of 
immunodominance seen for wild type HSV-1 (Fig 21B).  These data indicates that expression 
from the gCp results in a preferential retention of this minor infiltrating population, that becomes 
a delayed gB immunodominance by latency. As our previous data have shown that antigen 
expression in part drives a preferential retention of CD8+ T cell populations [155], the gC 
promoter is likely expressing at a low level throughout the establishment of latency. 
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Figure 21. gB498-505 expressed from gCp results in a delayed gB-CD8+ T cell immunodominance in 
ganglia 
 
Corneas of mice were infected as previously, with 1x105 PFU/eye of HSV-1 WT or recombinant HSV-1 
expressing gB498-505 from the gC promoter.  At 8, 10, 12, 16, 21, and 30 dpi TG were dissociated and 
stained with antibodies to CD45, CD3, CD8, and with MHC-I gB498-505 tetramer as detailed in Methods.   
(A) The total number of TG-infiltrating gB-specific CD8s is shown over time in a gCp infection. (B) The 
fraction of gB498-505 tetramer positive cells among the total CD8+ T cells in the TG is shown over time in 
each infection.  * denotes p<0.01 by one-way ANOVA. 
 
Viruses expressing the peptide from the UL38, UL41, and LAT promoters showed an 
even larger defect in priming of the gB-CD8 response, despite presenting gB peptide at levels 
similar to that from wild type infections in vitro by 24 hpi (Fig 17).  The reason for lack of 
priming is not clear, but reduced or absent priming from protein antigens expressed late in the 
growth cycle has been reported in other viruses[188, 189].  We note that while true-late genes 
form the majority of the HSV-encoded proteome, they are vastly underrepresented in the 
antigens recognized by an HSV-1 specific T cell response in B6 mice[77]. We then asked if 
these viral promoters were sufficiently active during latency to retain a gB-CD8 T cell response 
if such T cells were efficiently primed at the onset of infection.  We exploited the observation 
that at the time of the peak infiltrate into the ganglia at day 8, any activated systemic CD8 T cells 
will enter the acutely infected ganglia, independent of antigen presentation[155].   
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5.5 EPITOPE EXPRESSION FROM THE LAT PROMOTER RESULTS IN 
DELAYED LOW LEVEL GB-CD8 RESPONSES 
HSV expressing the gB epitope-GFP gene from the LAP did not induce a robust gB 
specific immune response like the viruses expressing the epitope from constitutive or γ1 
promoters. Nevertheless, a small but significant fraction of gB-CD8 T cells was detected in the 
systemic response (Fig 19C) and also in the latently infected ganglia at later times post infection 
over that seen for S1L (Fig 19D).  We therefore conducted additional studies on this virus to 
track the ganglionic gB-CD8 response.  While the LAP is weakly expressed in a lytic infection 
with γ2 kinetics, it was expected to be more active during latency.   
Quantification of the total gB-CD8s by tetramer staining over time revealed that while no 
gB-CD8s were seen at the peak of the infiltrate at day 8 post-infection, a small-but-significant 
fraction of ganglionic gB-CD8s developed by 20 dpi, which represented approximately 11% of 
the total contracted CD8 populations in the ganglia during latency (Fig 22A and B). This low 
level was maintained out to 60 dpi. To determine if this low late developing population was due 
to an expansion of a very low small population infiltrating the ganglia at the onset of latency, we 
performed BrdU pulse labelling for 2 days to identify dividing CD8+ T cells in the ganglia at day 
20 and 60 post-infection.  For wild type HSV-1, few cells were labelled at day 20 and day 60, 
indicating that the majority of the CD8+ T cells were not recently dividing.  However, the LAP 
virus did contain significantly more replicating CD8+ T cells at 20 dpi, and analyses with 
tetramer revealed the gB populations were expanding at 20 dpi (Fig 22C).  These cells were still 
undergoing a marginal expansion at day 60, significantly more than for wild type virus at both 
short- and long-term latency (Fig 22D).  
  85 
 
W
T
 D
9
W
T
 D
2
0
W
T
 D
3
0
W
T
 D
6
0
L
A
P
 D
9
L
A
P
 D
2
0
L
A
P
 D
3
0
L
A
P
 D
6
0
0
2 5 0 0
5 0 0 0
7 5 0 0
1 0 0 0 0
1 2 5 0 0
A b s o lu te  g B
+
 C D 8
+
 T  c e lls  in  T G
T
o
ta
l 
g
B
4
9
8
-5
0
5
+
C
D
8
+
 T
 c
e
ll
s
0.0226
0 2 0 4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
D a y s  P o s t In fe c tio n
%
g
B
+
 o
f 
C
D
8
+
 T
 c
e
ll
s
W T
LAP
P e rc e n t  g B
+
 o f  to ta l C D 8
+
 T  c e lls
W
T
 D
2
0
W
T
 D
6
0
L
A
P
 D
2
0
L
A
P
 D
6
0
0
2 0
4 0
6 0
P e rc e n t  B rD U +  T o ta l C D 8 +  T  c e lls
%
B
r
D
U
+
 C
D
8
+
 T
 c
e
ll
 i
n
fi
lt
r
a
te 0.0020
W
T
 D
2
0
W
T
 D
6
0
L
A
P
 D
2
0
L
A
P
 D
6
0
0
2 0
4 0
6 0
P e rc e n t  B rD U +  o f  g B -te t+  C D 8 +  T  c e lls
%
B
r
D
U
+
 g
B
+
 C
D
8
+
 T
 c
e
ll
 i
n
fi
lt
r
a
te 0.0271
0.0163
A B
C D
 
Figure 22. Latent expression of gB498-505 results in reduced and delayed gB-specific CD8+ T cell 
infiltrate 
 
Corneas of mice were infected as previously, with 1x105 PFU/eye of HSV-1 WT or recombinant HSV-1 
expressing gB498-505 from the LAT promoter.  2 days prior to harvest at 20 and 60 dpi, mice were pulsed 
with 1mg/mouse BrdU. At 9, 20, 30, and 60 dpi TG were dissociated and stained with antibodies to CD45, 
CD3, CD8, BrdU, and MHC-I gB498-505 tetramer as detailed in Methods.  (A) The total number of TG-
infiltrating gB-specific CD8s is shown over time. (B) The fraction of gB498-505 tetramer positive cells among 
the total CD8+ T cells in the TG is shown over time in each infection.  BrdU staining of (C) total CD8s and 
(D) gB498-505 specific CD8s is shown at 20 and 60 dpi. P-values shown represent significance by t-test. 
 
  86 
5.6 TRUE LATE AND LAP PROMOTER ACTIVITY IS SUFFICIENT TO RETAIN 
GB-CD8+ T CELL INFILTRATES PRIMED BY WT-HSV INFECTIONS 
LAP-driven antigen primed a negligible gB-CD8 response that was only detectable at late 
times post-infection within the latently infected tissue, and γ2 late promoters failed to prime gB-
CD8 responses at all. Therefore, we next asked whether these promoters can activate and retain 
WT-primed gB-CD8 responses within latently infected tissue.  We employed a dual infection 
strategy in which the ocular route was used for infection by the late promoter viruses, but a 
simultaneous flank infection with WT HSV-1 was used to systemically prime a gB-CD8 T cell 
response (Fig 23A).  At day 8, all ganglia infected with the non-priming HSV-1 were shown to 
contain gB-CD8s, consistent with the notion that recently activated CD8+ T cells will traffic to 
sites of infection (Fig 23B). As the CD8 population contracts at the onset of viral latency, only 
ganglia that harbor the cognate gB498-505 antigen can retain a sizable gB-CD8 infiltrate. At 
latency, greatly reduced levels of the gB-CD8s were seen in ganglia latently infected with S1L at 
latency, which does not express a recognizable gB epitope at any time.  For both viruses 
expressing the gB epitope under control of promoters that fail to prime a large initial response 
(UL38p, UL41p, and LAP), the level of gB-CD8s retained in the ganglia were at a level 
significantly higher than the gB-CD8s retained in the ganglia for S1L (Fig 23C).  The level was 
much lower for these two γ2 promoters than that seen for viruses expressing peptide under 
control of LAP, the latency active promoter.  We conclude that expression of the peptide from 
these true late promoters is not sufficient to prime a significant gB-CD8 T cell response. 
However when such a response is effectively primed from the flank, the low level of γ2 late gene 
expression within the ganglia is sufficient to activate and retain a small number of CD8+ T cells 
within the latently infected ganglia. In contrast, the LAP can efficiently retain a much larger gB-
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CD8 response, consistent with the idea that this promoter expresses during CD8+ T cell 
contraction and latency. Taken together with the data from Figure 22, this indicates that the 
kinetics of LAP in a lytic infection are not sufficient to induce antigen levels sufficient for 
priming a large CD8+ T response. However, during latency LAP-driven antigens are sufficient to 
mediate efficient ganglionic retention driven by ongoing antigen expression, and in these cases 
poor priming and generation of tissue-resident memory gB-CD8s can be bypassed by priming 
the responses at another location on the animal.  
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Figure 23. True late or latent promoters deficient in priming gB-CD8s are capable of maintaining 
more gB-CD8s at latency 
 
(A) Representation of infection model in which mice received bilateral corneal infections with S1L, UL38p 
or UL41p HSV-1 and flank infection with WT HSV-1.  All corneal infections were with 1x105 
PFU/scarified cornea, and flank infections were with 1x106 PFU on a scarified flank. (B and C) At 8 
(acute) or 30 (latent) dpi, TG suspensions were analyzed by flow cytometry for CD45, CD3, CD8, and 
gB498-505-tetramer.  Frequency of CD3+CD8+ T cells in the TG that are gB-tetramer+.  5-10 mice analyzed 
per group. Statistical significance by one-way ANOVA displayed above each group at latency.  
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5.7 HSV-1 EXPRESSING AN MCHERRY-GB-PEPTIDE FUSION PROTEIN FROM 
THE UL41 GENE 
Further considerations need to be taken into account when addressing the lack of CD8+ T 
cell priming by gB498-505 peptide expressed as a γ2 gene, as seen with both the UL38 or UL41 
promoters. In all the promoter-peptide constructs that were presented within this chapter, the 
gB498-505 peptide was expressed as a 4mer-gB494-509 peptide fused with EGFP, which proved to be 
rather unstable and not easily detectable by fluorescence or western blotting (data not shown). 
This is actually advantageous for efficient antigen presentation, as unstable proteins are rapidly 
degraded and peptides become available for MHC-I presentation. However, this construct may 
differ greatly in peptide-protein stability and subcellular localization when compared to HSV-1 
epitopes derived from native viral proteins. In a WT HSV-1 infection, the gB498-505 peptide is 
located within the gB protein, which is located both on the membranes of infected cells, and as 
part of the array of viral glycoproteins displayed on the viral envelope (Fig 1).  
To address this discrepancy with antigenic stability, we tested several fluorescent-
protein-gB494-509 fusion constructs. Among these, we created an mCherry protein either N- or C- 
terminally tagged with a single copy of gB494-509 expressed from the UL41 locus. These 
recombinant viruses express gB494-509-mCherry as a bicistronic message linked to UL41 
expression by utilizing a T2A linking sequence, and this construct was generated in the S1L 
background (Fig 24A). These viruses all have very bright mCherry fluorescence, and detectable 
mCherry protein by western blot, indicating greatly increased stability compare to the EGFP-
linked peptide used in earlier studies (data not shown). When these viruses were tested for ability 
to present peptides in gB-CD8 T cell cocultures with infected fibroblasts as detailed for Fig 17, 
maximal presentation was detected by 24 hpi, consistent with γ2 late gene kinetics (Fig 24B). 
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Figure 24. UL41-T2A-mCherry linked gB-peptide viruses present gB498-505 peptide with kinetics 
similar to UL41p virus 
 
Confluent B6WT3 cells were infected with approximately 1x106 PFU at an MOI of 1 with WT HSV-1, 
S1L, 41p, 41-gB-mCherry or 41-mcherry-gB. At 4, 8, or 24 hours each plate was UV-inactivated (with less 
than 10 PFU remaining per well), and combined into coculture with 1x105 splenic cells derived from an 8 
dpi infected gB-T mouse for 6-8 hours in the presence of Brefeldin A. Cocultures were then stained for 
CD45, CD8, IFNγ and TNFα. Quantitation of representative of the total number of IFNγ+ CD8+ T cells per 
coculture stimulation shown. 
 
Mice ocularly infected with these gB-peptide recombinant viruses containing gB-
mCherry (N-terminal fusion) or mCherry-gB (C-terminal fusion) show a varying ganglionic 
gB498-505 specific CD8 response (Fig 25). Unexpectedly, the N-terminal mCherry peptide fusion 
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elicited an intermediate amount of gB-CD8 infiltrate (~18% of total CD8s), while the C-terminal 
version was not significantly different from the control mCherry virus that does not contain the 
gB-peptide. This trend was also seen systemically, in the spleen, and suggests that the C-terminal 
fusion does not prime gB-CD8s, while the N-terminal version does (data not shown). These 
results do not reflect the amount of gB-epitope detected in the in vitro presentation assay in 
figure 24B, and further studies need to be done to explain this phenomenon.  
 
Figure 25. UL41-T2A-mCherry linked gB-peptide viruses elicit differing CD8+ T cell responses 
 
Corneas of mice were infected with 1x105 PFU/eye of HSV-1 WT UL41-gB-mcherry, UL41-mcherry-gB, 
or UL41-mCherry-ctrl.  At 9 dpi (peak CD8+ T cell infiltrate) TG were dissociated into single cell 
suspensions and surface stained with antibodies to CD45, CD3, CD8, and with MHC-I gB498-505 tetramer as 
detailed in Methods.  Cells were subsequently analyzed by flow cytometry and show total CD8+ T cells per 
TG. 
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5.8 DISCUSSION 
Factors that determine which antigens of a pathogen are targeted by the developing 
cellular immune response, and the hierarchal order of the antigens targeted, are complex and 
multifactorial[158].  The B6 mouse model is unique in that the dominance hierarchy is so heavily 
skewed to one epitope, for reasons that are not entirely clear. One aspect that may contribute to 
the immunodominance pattern is the activity of the promoter— it may be that the gB promoter is 
ideally suited to generate a highly skewed response in the B6 mouse. Secondly, it has become 
apparent that an additional level of complexity governs the hierarchy of the CD8+ T cell immune 
response associated with the HSV ganglionic latent state, since it is not only influenced by the 
antigenic repertoire of CD8+ T cells primed, but also by the viral gene expression events that 
sporadically occur during HSV-1 latency[66, 67, 162].  Several lines of evidence strongly 
indicate that a majority of CD8 T cell ganglionic retention during the HSV-1 latent state requires 
antigen expression[146, 155].   These observations were the driving factors in the hypotheses 
behind the current study: do different promoters driving the expression from the HSV genome of 
a strong immunodominant HSV-1 CD8+ T cell epitope in B6 mice (gB498-505 [SSIEFARL]) 
influence the proportion of gB-CD8 T cells in the ganglionic population at latency?  We were 
particularly focused on determining if the proportion of gB-CD8s in the latently ganglia could be 
numerically increased by use of predicted strong promoters, given the fact that gB-CD8s are 
more active and able to better prevent reactivation events in WT infections[155]. 
We concluded that the promoter selected to express the epitope in the context of HSV 
genomes can influence both the priming efficiency of the CD8+ T cell response and the long-
term retention in the latently infected murine ganglia.  While several of the promoters evaluated 
expressed HSV-1 epitopes to levels that efficiently primed a CD8+ T cell response, we saw quite 
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different responses and priming with the epitope expressed from three true late and the Latency 
associated gene promoters.  Recombinant viruses developed here to express gB498-505  epitope 
from the various promoters (Table 1) used a recently described single amino acid mutation (S1L) 
mutated in the gB498—505 epitope that ablates gB CD8
+ T cell priming and recognition[155].  This 
strategy separated the epitope from the gB protein, and allowed us to examine the CD8+ T cell 
response in viruses that were comparatively pathogenically fit in the murine model.  This 
strategy was necessary because a previous similar study aimed at addressing the contribution of 
promoters to immunodominance used a virus in which the expression of the whole gB was 
altered to a true late gene. This resulted in a considerable cost in viral fitness and a resulting 
altered development and ganglionic infiltration of the HSV-specific CD8 T cell response [153].  
All recombinant viruses used here induced ganglionic latent loads at least as efficiently as wild-
type virus and a total peak of the immune infiltrate in the ganglia similar to WT-equivalent total 
CD8+ T cells.  Some viruses were slightly more efficient than wild-type at establishing a latent 
load. The basis for this was not clear, since in comparing these viruses, all promoters were at the 
same ectopic locus, in the gC gene.  While this had the caveat that the strategy might not 
completely reflect the full range of expression from the native loci or the promoter, it also 
reduced any influence of genomic location or the behavior of the CD8+ T cell response across 
multiple viruses.  Disruption of the gC open reading frame had no observable effect in our mouse 
model of scarified corneal infection, seen here or in previous studies [23, 179].  Thus, all 
differences seen in the CD8+ T cell responses are the result of contribution of the different viral 
promoter activities.  
  A second conclusion is that the gB promoter is not necessarily a “goldilocks” promoter, 
and other promoters can easily generate a strongly primed gB immunodominant phenotype. Most 
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intriguingly, all promoters in the subset of viruses that primed a significant gB-CD8 T cell 
response resulted in a near identical fraction of gB-CD8s at latency— even in the case of the gC 
promoter, where there was a small fraction of gB-CD8s primed that were selectively retained to 
become immunodominant by late times (Fig 21). Thus, it does appear that increased lytic 
expression of an epitope does not necessarily lead to increased level of CD8+ T cell 
immunodominance in the ganglia as we hypothesized.  In a WT HSV-1 infection, glycoprotein B 
is expressed as an γ1 leaky-late gene that is, nevertheless, capable of being detected within two 
hours post-infection [185].  Here, HSV with constitutively active regulated CMVp and α 
regulated ICP0p driven expression of the epitope showed only marginal differences in the 
priming of the splenic gB-CD8 T cell response, despite the observation that these viruses could 
activate over five times as many CD8+ T cells by four hours post infection in in vitro activation 
assays over that by wild type HSV-1.  There is a caveat that we cannot establish that these 
promoters are more active than the gB promoter in the latently infected murine ganglia, but the 
CMV promoter has been found to be active from the HSV genome for up to 30 days in the 
murine TG, and the ICP0 protein is needed for reactivation [190] .  However, we also increased 
the amount of epitope expressed from the gB promoter during latency, using a multimeric 
peptide strategy. This approach did not increase immunodominance levels in the latently infected 
ganglia, even though it clearly increased levels of the epitope made in a lytic infection from the 
respective gB promoter on the surface of infected cells (Fig 17).  The VP16 promoter was as 
active as gB promoter and did not result in a higher immunodominant response.  We examined 
VP16p since it has been reported to be a possible pre-α gene that precedes immediate-early genes 
in sporadic reactivation events from ganglia[62, 180].   We conclude that for this subset of the 
viruses, the minimal ganglionic expression level required to retain robust gB-CD8 infiltrates 
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during the onset of latency was reached for each virus.  This implies that expression above this 
minimal level neither primes a more immunodominant CD8+ T cell response nor maintains a 
higher level of immunodominance during latency than that seen for WT virus.  What defines this 
limit is not yet clear. It is possible that any promoter will only drive a limited level of gene 
expression during latency that is defined not by the activity of the promoter in lytic context, but 
how its repression is influenced by chromatin changes that defines the TG immunodominant 
population and the sporadic reactivations that act to retain them. 
An additional minor (if negative) conclusion was the observation that, in the entire CD8+ 
T cell repertoire to HSV in B6 mice, there are no representative CD8 populations targeting 
epitopes on α proteins. We considered the possibility that α expressed proteins might have 
unique properties that act to prevent their ability to prime the CD8+ T cell response.  However, 
this does not seem to be the case, since α promoter driven expression of the epitope stimulates a 
robust and strong immune response.  Taken together, while one of the goals of this project was to 
create a virus that rapidly expressed a large amount of gB498-505 epitope, as this immunodominant 
epitope elicits a CD8+ T cell response that remains particularly active and capable of effector 
functions throughout latency in C57Bl/6 mice, it seems that this is not easily achieved by altering 
epitope expression alone.  There seems to be an unidentified mechanism preventing tissue-
specific CD8+ T cell responses from becoming skewed completely to one epitope. This 
mechanism is likely to involve cytokine competition within the TG, competition for antigen, 
viral immune evasion strategies, and other factors [158, 188]. One possibility is that as viral 
gB498-505 antigen is detected and shut down by gB-CD8s, there is less antigen available for other 
gB-CD8s to detect, leading to an inability to rise above a certain threshold of gB-CD8s. From a 
host evolutionary perspective, it also makes sense to not focus all attention on one epitope, which 
  95 
would provide opportunities for viral escape mutants, and therefore there may be interactions 
among specific CD8 populations preventing full immunodominance within the tissue. 
  In contrast to the early and strong lytic promoters, γ2 late promoter driven epitopes from 
UL38p or UL41p demonstrated a greatly reduced ability in both priming gB-CD8 responses and 
in retaining CD8s in the ganglia when the gB498-505 response is exogenously primed by a wild-
type infection.  These two promoters were clearly active during lytic infections, since in vitro by 
24 hpi, both viruses could elicit gB-CD8+ T cell activation levels that equaled or exceeded the 
WT virus response (Fig 17).  However, they were less active than the strong/immediate early 
promoters, and neither virus was able to activate a significant fraction of the gB CD8s at 4h post 
infection, consistent with the delayed expression expected for a true late promoter.   The non-gB-
CD8 T cells that make up the rest of the response have been thoroughly characterized  for S1L 
[77], and we have previously shown that expansion of the subdominant responses occur when gB 
responses fail to prime[155], and we assume that a similar compensation occurs for these viruses.  
Why these promoters did not efficiently prime a response is not clear. However, it has come to 
light that generating effector-memory CD8+ T cells requires several naïve T cell interactions 
with DCs in the draining lymph nodes[191, 192], with epitope being presented on specific 
dendritic cell subsets, and cross-presented by other DC subsets being vital steps in generating 
memory CD8+ T cell responses. Altering both the expression kinetics of the peptide as well as 
the location within the protein— resulting in a terminal peptide multimer instead of a residue 
within the gB gene—may very well change the amount of epitope that these DC populations 
have access to via either direct or cross-presentation. Finally, we note that both γ2 promoters 
could retain an exogenously primed gB-CD8 T cell response, but at levels nowhere near that 
seen for the active viruses detailed above.  This suggests that these promoters might be less 
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active during latency than others, but does indicate there is a low-level of late gene expression 
within the ganglia.  This would fit with our previous observation that the subdominant 
population hierarchy retained in the S1L latently infected TG is quite different from the systemic 
response, suggesting that some promoters are more active during latency than others, and thus 
their cognate CD8+ T cell populations are selectively retained. Different rates of firing of 
sporadic reactivation for different promoters were also seen by the Tscharke group[67].  This 
conflicts with the general de-repression model put forward by Wilson and colleagues [62], and 
suggests that there are genomic regions that are preferentially active in sporadic reactivation 
events.  
Intriguingly, we found that the gC and LAP promoters show different patterns of priming 
and retention.  In lytic infections, gC is a γ2 late gene that strictly requires new viral DNA 
synthesis for expression, but it appears to express at levels higher than the UL38 and UL41 
promoters by 24 hpi in gB-CD8 T cell activation assays (Fig 17).  In mice, the primed splenic 
responses were considerably reduced in comparison to the WT, gBp, CMVp and ICP0p (Fig 4C). 
More strikingly, TG infiltration of gB-CD8s were delayed compared to WT, with only about 
10% of the ganglionic CD8s being gB-specific at day 8 (Fig 21), as compared to 50% for a wild 
type infection.  Our data suggests gB CD8+ T cells are retained very efficiently for this virus and 
become a typical immunodominant population seen during latency.  This suggests that the gC 
promoter is sufficiently active to drive priming of the gB-CD8 population, but the activity of the 
promoter during latency is above the minimal level that is required for 50% immunodominance 
just discussed.    This fits well with data from studies in which both gC RNA and protein were 
both found to be expressed during latency [67, 193, 194]. 
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Finally, the LAP promoter shows a unique pattern in priming and ganglionic retention.   
In lytic infections, the full 2kb LAT promoter driving expression of gB498-505 from an ectopic 
locus induced some expression by 24 hpi, and activated a small number of in vitro gB-CD8s 
compared to wild-type virus (Fig 17).  While HSV LAT is known to be active during latency, it 
has previously been reported to be expressed during lytic infection, with kinetics of a late 
regulated gene[195].  The LAT promoter virus showed very little priming within the time of the 
initial infection of B6 mice, with such a small splenic response that it was not significantly 
different from the epitope knockout (S1L, Fig 17).  However, mice infected with this virus over 
time develop a significant expansion of gB-CD8s into the murine TG (Fig 22A). This expansion 
correlates with an increase in BrdU uptake by these gB-CD8s clearly demonstrating that they are 
likely seeing expressed antigen (Fig 22C-D). This gB-CD8 expansion is maintained as a 
significant percentage (~10%) of the CD8 response throughout latency, despite a virtually 
undetectable priming of the gB-CD8 response at acute times post-infection (Fig 22B). This 
suggests that the levels of protein generated in the context of the initial priming is insufficient to 
compete with all other viral antigens and primer a gB CD8 response. However, with LAP-driven 
continuous expression of gB peptide, CD8+ T cells are subsequently primed during a time when 
there are few other antigens to compete.  Remarkably, in the dual flank infection model, 
exogenous priming  results in an efficiently retained gB-CD8 population in the TG.  This 
suggests that the LAP promoter could be used to maintain a CD8+ T cell population in the 
ganglia, but only when the T cells are efficiently primed[155]. 
We considered that there may be differences in the functionality of the ganglionic CD8+ 
T cells retained by expression from the different promoters.  Function and exhaustion are both 
influenced by chronicity and levels of antigen expression in the LCMV models[196]. In previous 
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studies with wild type HSV, gB-CD8s show a more functional phenotype and demonstrate better 
anti-viral effector properties than their non-gB-CD8 counterparts[77, 148, 155], as indicated by 
increased expression of the activation marker GzB and decreased expression of the exhaustion 
marker PD-1.  We found that there was a global trend for increased GzB and reduced PD-1 on 
gB-CD8s generated by all gB promoter viruses (Fig 20).  There were, however, a few minor 
differences. The gB CD8s retained by the CMVp virus show a higher level of PD-1 and lower 
level of GzB, which suggests they may have started to become exhausted due to more epitope 
expression within the TG. However, with all viruses the general trend is intriguingly similar, 
demonstrating that even with an apparent large difference among expression levels, the 
immunodominant gB-CD8s remain more activated and functional than their subdominant 
counterparts in the TG. 
From our studies with the N- and C-terminal linked gB498-505 peptide linked to mCherry 
in the UL41 gene, it is also clear that kinetic class is only one of a myriad of factors that 
determine CD8+ T cell priming deficits in γ2 late genes. By creating a more stable protein to link 
gB peptide to, we saw somewhat different results. The N-terminally linked gB-mCherry 
expressed from the UL41 locus generated an intermediate gB-CD8 infiltrate at acute times, 
similar to what was seen for the gCp virus during acute infection, while the C-terminal version of 
this construct failed to prime gB-CD8s, despite higher levels of detectable gB498-505 presentation 
in vitro (Fig 24 and 25). It would be telling to follow the gB-mCherry virus out to later time 
points to determine if these gB-CD8s are retained more efficiently as is seen in the gCp virus. It 
also is of note that N- or C-terminal positions of the peptides may be processed differently in 
APCs in vivo, despite the retained gB494-509 processing sites surrounding the peptide [197].  
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Taken together, these data begin to paint a picture in which viral antigen expression 
kinetics play a role in shaping ganglionic CD8+ T cell responses associated with HSV-1 latency.  
Not surprisingly, stronger lytic promoters can dictate the efficiency of priming of the effector 
CD8+ T cell responses, but it also becomes apparent that promoter activity driving expression 
within the TG itself is important for retention of these responses. Furthermore, the fact that TG-
resident/tissue-specific CD8+ T cell responses associated with HSV latency do not necessarily 
reflect the splenic and systemic responses is not surprising. However, as latency progresses, viral 
gene expression significantly shapes the protective CD8 repertoire that patrols the TG and 
prevents reactivation. 
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6.0  VACCINATION STRATEGIES FOR PRIMING GANGLIONIC GB498-505 CD8+ T 
CELL RESPONSES UTILIZING AAV OR PRV VECTORS 
Current evidence supports that a short burst of ganglionic replication follows initial 
infection with HSV-1, which contributes significantly to the latent viral load in the TG [198]. 
This is consistent with the detection of infectious virus at 2-4 dpi that we routinely observe in the 
TG, which is controlled by macrophages and γδ T cell-dependent expression of effector 
molecules such as IFNγ and TNFα by 6 dpi [101]. Given that protective CD8+ T cell infiltrates in 
the TG are capable of mounting similar cytokine responses, expression of gB498-505 in the TG and 
the establishment of a pre-existing CD8+ T cell population prior to HSV-1 infection has been 
hypothesized to lessen this replicative burst and reduce the viral genomic load in the TG. 
Furthermore, superinfection with gB498-505 expressing vectors after HSV-1 latency has been 
established may augment the infiltration and functionality of CD8+ T cells. The vectors to be 
evaluated in this chapter include adeno-associated virus (AAV) and an attenuated pseudorabies 
virus (PRV). 
Wild-type AAVs are replication defective viruses that need a helper virus to reproduce. 
This fact makes AAV one of the safest available viral vectors for gene delivery, although a 
limited amount of genetic material can be packaged. AAV transduced gene products can persist 
for weeks to months in long-lived cells such as neurons, which also adds to their potential[199]. 
AAV serotypes 2, 5 and 8 have been shown to be neurotrophic in some models, with some 
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serotypes having the ability to efficiently transduce dorsal root ganglia (DRG) from surface 
applications implying the ability to transduce sensory ganglia through neuronal axons [200-203]. 
This is important for our model of ocular infection, as there is an abundance of sensory nerve 
termini in the cornea. 
PRV is an Alphaherpesvirus similar in structure to HSV-1, and which causes a naturally 
occurring infection of swine and bovines. PRV has been researched for decades as a model 
neurotropic Alphaherpesvirus, due to its ability to quickly and efficiently target and traverse 
axons in many model organisms[204-208]. This in part explains the severe infection of the 
nervous system observed in mice, rats, guinea-pigs, rabbits, and other mammals, in which a 
wild-type PRV infection is fatal. PRV strains lacking Thymidine Kinase (TK) gene expression, 
however, are unable to replicate efficiently in neurons, making them suitable as neurotrophic 
delivery vehicles for target gene expression[209]. TK- viruses are fully replication competent 
within epithelial tissues, with large inflammatory responses that are ideally suited to prime 
efficient memory CD8+ T cell responses. To our knowledge, the use of PRV on mouse corneas to 
target TG neurons had not been attempted previously. 
6.1 USING AAV TO TARGET TG NEURONS BY OCULAR INNOCULATION 
To first test the ability of AAV to transduce TG neurons, we chose AAV2, 5, and 8 
reporter constructs that express EGFP from the CAG promoter, a strong synthetic promoter 
designed to elicit very high persistent levels of target gene expression. B6 mice were ocularly 
treated with the AAV vectors in the same way HSV treatments were described earlier. We 
abrade the surface of the cornea to expose sensory nerve termini, then apply 1*10^10 genome 
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copies (gc) of AAV. Animals were examined at 2, 8, and 20 days post-inoculation and TG and 
cornea examined for reporter gene expression by both qPCR for EGFP, and tissues were 
mounted on slides and examined for EGFP by fluorescence microscopy.  
In all AAV reporter constructs tested, no significant EGFP expression was observed 
within the TG, and similarly no EGFP mRNA was detectable by qPCR (data not shown). 
However within the cornea, large numbers of corneal stromal cells expressed EGFP, as 
determined by fluorescent microscopy of a whole corneal mount inoculated with AAV8-EGFP 
(Fig 26). Similar results were observed with AAV-2, albeit to a lesser extent, and no target gene 
expression with AAV5 was observed. 
 
Figure 26. Whole corneal showing AAV8-EGFP target gene expression. 
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Anesthetized B6 mice were scarified and inoculated with 1*10^10 gc/eye with AAV8-EGFP. At 20 days 
after treatment, mice were sacrificed and whole-corneal mounts DAPI-stained and imaged for EGFP 
expression. 
 
 
Targeting TG via sensory nerve endings from the cornea proved to be more difficult than 
was seen in skin-DRG models, which may in part be due to the neural-crest lineage of corneal 
stromal cells when comparted to skin [201-203, 210]. Given the lack of TG-neuron targeting, we 
did not proceed with generating an AAV that expresses gB498-505, or developing an adjuvant 
strategy to induce CD8+ T cell priming. It became clear from these data that we would benefit 
from the use of a strongly neurotropic virus for this model, and PRV was chosen for this reason. 
6.2 DESIGNING PRV THAT EXPRESSES GB498-505 
To reduce neuronal spread of PRV vectors, we first generated all PRV as TK knockout 
(PRV TK-) by inserting a cassette that consists of monomeric red fluorescent (mRFP, mRed) 
gene expressed from the TK promoter which disrupts the TK ORF. PRV that expresses the HSV-
1 gB498-505 peptides was generated in a similar fashion, with an additional PRV-gB or CMV 
promoter driving expression of gB498-505 linked to EGFP (Fig 27).  
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Figure 27. Schematic detailing construction of PRV expressing HSV-1 gB498-505 
6.3 PRIMING HSV-1 GB-CD8+ T CELL RESPONSES WITH PRV-GB498-505 
PRV TK-. CMVp, or gBp were grown to high titer and confirmed by gB-CD8 T cell 
cocultures to express gB498-505 that was readily detectable. B6 mice ocularly infected in a similar 
fashion to HSV studies carried out previously. At either acute (9 dpi) or latent (33 dpi), TG of 
mice were harvested and assessed by flow cytometry for CD8+ T cell responses. Compared to 
WT HSV-1 at 9 dpi, PRV induced CD8+ T cell responses nearly as large as WT HSV (Fig 28A). 
When gB498-505 specific CD8
+ T cells were analyzed with tetramers, a large percentage of the 
PRV immune response was directed toward the gB498-505 epitope, accounting for nearly a third of 
the total CD8 infiltrate (Fig 28B). This was surprising, given that PRV has its own array of 
virally encoded peptides that CD8+ T cells can recognize. Of note, there is little-to-no overlap of 
CD8+ T cell epitopes between wild-type HSV-1 and PRV, as demonstrated by sequence analysis, 
and by stimulation assays seen in Figure 11C, where the HSV-1 S1L-specific CD8+ T cell 
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repertoire was not stimulated by PRV-gB498-505 infected fibroblasts. By 33 dpi, there remained a 
large CD8+ T cell infiltrate in the ganglia, of which almost half was gB498-505-specific. This was a 
very promising result for the goal of priming an HSV-1 specific CD8+ T cell response within the 
ganglia, but upon further analysis several problems arose that prevented use of PRV as a 
prophylactic HSV-1 vaccine, as described below.  
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Figure 28. CD8+ T cell responses to PRV vectors expressing HSV-1 gB498-505 
Corneas of mice were infected with 1x105 PFU/eye of recombinant PRV vectors expressing gB498-505 from 
the indicated promoter or WT HSV-1. At 9 dpi (near the peak of CD8+ T cell infiltrate) or 33 dpi (viral 
latency), TG were dissociated into single cell suspensions and surface stained with antibodies to CD45, 
CD3, CD8, and with MHC-I gB498-505 tetramer as detailed in Methods.  Cells were subsequently analyzed at 
9 dpi by flow cytometry and show (A) total CD8+ T cells per TG and (B) the total percentage of gB498-505 
tetramer positive CD8+ T cells in each TG also shown. Identical studies were carried out at 33 dpi showing 
(C) total CD8+ T cells per TG and (D) the total percentage of gB498-505 tetramer positive CD8+ T cells. 
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6.4 OCULAR DISEASE IN PRV-INFECTED MICE 
Between the acute and latent time points shown in the previous figure, it was observed 
that mice infected with TK- PRV began showing signs of severe HSK. When scored clinically 
for corneal sensation, almost all mice in PRV-infected groups had lost the blinking reflex usually 
observed when gently touching the corneal surface (Fig 29A). Accompanying the loss of corneal 
sensation was a severe keratitis, with very high opacity and blood vessel ingrowth into the inner 
cornea by 33 dpi (Fig 29B, C). By all appearances this disease is quite similar to a very 
pathogenic HSV-1 infection, which results in a similar phenotype. In the case of HSV-1, severe 
loss of corneal blink reflex as observed here is accompanied with a retraction of sensory nerve 
termini from the cornea, along with a subsequent ingrowth of sympathetic neurons that prevents 
sensory nerves from returning[211, 212]. This loss of sensory nerves and sensation contributes 
greatly to the keratitis disease phenotype, and may explain what is happening in our PRV model 
as well. 
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Figure 29. Corneal pathology in PRV infected mice 
At 33 dpi, the corneas were examined for (A) corneal blink reflex, (B) corneal opacity as observed under 
slit-lamp microscopy and (C) degree of vascularization. Corneal reflex measured as a simple 
positive/negative ability to blink upon gently touching all quadrants of the cornea with a surgical spear. 
Corneal opacity is measured on a 0-4 scale for severity of opacity, as confirmed by two observers. 
Similarly, the severity of blood vessel ingrowth was measured on a 0-4 scale for vascularization extent 
across corneal quadrants by two observers. 
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To determine whether our PRV vectors were able to remain latent in the TG over the time 
measured, we performed qPCR for PRV glycoprotein H (gH) on DNA isolated from 9 or 33 dpi 
TG (Fig 30). At early time points, low levels of PRV genomes were readily detected in most 
samples, however at later times, no PRV genomes were detected. This suggests either clearance 
of viral DNA or death of infected neurons. Given the severity and rapid onset of the corneal 
disease, it seems likely that our PRV vector damaged or killed TG neurons innervating the 
cornea. A follow-up study looking for apoptotic markers within TG latently infected with PRV 
would allow us to address this question. 
 
Figure 30. Genome copy numbers of PRV in infected TG at early and late times post infection 
Genome copy number determined by qPCR in the TG of mice ocularly infected with 1x10^5 PFU of TK- 
PRV vectors expressing mRFP alone, or an mRFP cassette containing the HSV-1 epitope gB498-505 
expressed from either the PRV gB promoter, or the CMV promoter (n=3-4 mice per group). HSV infected 
control mice were infected with 1x10^5 PFU WT HSV-1 and treated identically. At 9 or 33 dpi, TGs were 
harvested, DNA isolated, and qPCR performed with primers specific for PRV gH. PRV BAC standard used 
as a positive control for detection, as well as calculations for viral copy number. Values are representative 
of the total copies per 100ng of TG DNA recovered.  Dotted line indicates lower threshold of detection. 
  110 
 
Given the potential therapeutic benefits of developing a ganglionic CD8+ T cell vaccine, 
it is unfortunate that the strategies employed here were not more successful. While it was 
possible to generate a large HSV-specific CD8 response, the PRV vectors employed appear to be 
unsuitable for testing as prophylactic HSV-1 ganglionic T cell vaccines.  
 
  111 
7.0  SUMMARY AND CONCLUSIONS 
Most HSV-1 disease, including potentially blinding herpes stromal keratitis, results from 
sporadic reactivation of latent HSV-1 within sensory ganglia.  Latently infected ganglia of 
humans and mice contain a persistent immune infiltrate of CD4+ and CD8+ T cells, with 
ganglionic CD8+ T cells capable of blocking HSV-1 reactivation from ex vivo cultures of latently 
infected ganglia.  The studies presented within this dissertation first describe the nature of a 
CD8+ T cell response directed to the S1L gB epitope mutant of HSV-1. We first demonstrate 
that the S1L mutation in gB generates a virus that is as fit as WT, but lacks the ability to be either 
primed or recognized by gB-CD8s. By ablating the immunodominant response that occurs in B6 
mice, we were able to define the nature of the compensatory response. HSV-S1L infection 
primes an identically sized CD8+ T cell response during both acute and latent infection, but the 
makeup of the subpopulations of antigen-specific T cells is very different from mice infected 
with WT virus.  
At peak CD8+ T cell response times post-infection, the TG-infiltrating CD8+ T cell 
population in S1L shows a general increase in all subdominant epitope-specific CD8s that were 
previously identified[77]. By latency, when subdominant CD8+ T cell that recognize the 19 
subdominant viral epitopes are generally exhausted and unresponsive to stimulation in WT 
infections, these same non-gB-CD8s are not only numerically enhanced, but show more function 
within latently infected ganglia.  We also demonstrate by using a flank model of priming gB-
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CD8s with WT coinfection, that gB-CD8s enter S1L infected ganglia, but are not retained in 
large numbers. This demonstrates that there is a strict requirement for antigen detection within 
the TG for maintaining memory CD8+ T cell populations. It also suggests that the preferential 
retention of select RR1-, ICP8-, and UL28-specific CD8+ T cells (shown in Figure 14) is in part 
due to ongoing MHC-I presentation of viral peptides and their detection during the establishment 
and/or maintenance of viral latency. Understanding the interplay between recognition of this 
viral protein, and how this shapes CD8+ T cell effector function is vital to developing methods to 
maintain HSV-1 in its latent state and enhance blockade of late phase 1 reactivation events 
before they progress. 
 We next examined the effects of varying the promoter that drives gB498-505 epitope 
expression to determine how viral promoter activity within the TG shapes the resident CD8+ T 
cell populations. A panel of viruses that ectopically express this peptide from constitutive, 
immediate early, late, or latently active promoters was developed in HSV-1 S1L. We 
demonstrate that cells infected with these viruses effectively present gB498-505 to gB-CD8s in 
fibroblast coculture experiments. Thus, all infected fibroblasts were able to activate as many gB-
CD8s as in WT infection, by late timepoints. We also confirmed by this method that promoter 
activity followed the general kinetic trend expected, with early promoters activating gB-CD8s 
within four hours of infection, and some late promoters not being recognized until almost 24 hpi. 
These gB498-505 promoter viruses allowed us to determine whether the immunodominance or 
number of CD8+ T cells within latently infected TG can be altered by use of more active or 
earlier expressed viral promoters, and whether epitope expression from late or latently active 
promoters alter the development of the CD8+ T cell response and ganglionic retention. 
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In all promoter viruses tested, equivalent numbers of CD8+ T cells were seen in the TG 
throughout the acute and latent stages of infection. However, these viruses differed significantly 
in their ability to prime gB-CD8 responses in mice. Ectopic epitope expression from the gB 
promoter restored full gB-CD8 immunodominance.  Expression from stronger constitutive, 
immediate early, and early promoters did not increase the level of immunodominance above that 
of WT HSV-1, suggesting a maximal level in this model had been reached.  However, epitope 
expression from candidate viral γ2 gene promoters resulted in delayed or severely reduced 
priming efficiency of gB-CD8s, resulting in the compensatory CD8+ T cell response of non-gB-
CD8s previously described in the parental S1L virus.  Epitope expression from the LAP failed to 
efficiently prime CD8s, with numbers not significantly different from S1L during the peak CD8+ 
T cell infiltration. However, this virus could efficiently expand and retain a small population of 
gB-CD8s as other CD8+ T cell populations were contracting, suggesting an increased level on 
ongoing recognition during the establishment of latency. These data are reminiscent of the RR1, 
ICP8, and UL28 specific memory CD8+ T cell populations that become prominent during latency 
within the S1L virus due to preferential retention of these populations during the contraction 
phase.  
We also tested the effects of peptide location and antigen stability within the context of 
the ability for a γ2 late gene to prime a CD8+ T cell response. By using a stable mCherry-gB498-
505 expressing virus, we demonstrated that not only do the kinetics of expression alter the ability 
to prime efficient CD8+ T cell responses, but so does the context of peptide location within the 
protein. Taken together, these data indicate that choice of viral promoters and context of peptide 
expression will influence the priming and ganglionic retention of CD8+ T cell populations. 
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 Given the ability of HSV-1 specific CD8s to remain within the latently infected tissue 
and monitor viral gene expression and reactivation, it would be very advantageous to establish an 
HSV-1 specific CD8+ T cell population within the TG prior to the primary infection. To this end, 
we attempted to generate alternate viral vectors to prime CD8+ T cell responses and deliver 
HSV-1 epitope to the ganglia. AAV would be an ideal method of delivery, as it is quite 
innocuous and nonpathogenic to the host, but targeting TG axonal termini by topical 
administration proved more difficult than expected. Conversely, an attenuated PRV vector was a 
potentially ideal choice for targeting sensory nerves within the cornea, and indeed PRV 
expressing gB498-505 elicited a strong gB-CD8 response both systemically, and within the TG 
compartment. However, PRV had the unanticipated consequence of causing severe corneal 
disease— likely as a result of substantial damage to TG neurons, leading to loss of corneal 
innervation. 
 There are myriad factors within the latently infected ganglia that contribute to efficient 
CD8+ T cell control of viral reactivation. In this work we demonstrate that there is ongoing CD8+ 
T cell recognition within the ganglia that leads to preferential CD8 populations becoming 
dominant. This immunodominance is determined by a combination of host naïve T cell repertoire 
and selection, viral gene expression, and likely also competition between CD8+ T cell 
populations within latently infected ganglia (possibly competition for antigen, cytokine, or 
costimulatory factors). By altering the amount and timing of antigen expression within the 
latently infected TG environment, we can partially control which memory T cell populations are 
present and functional. We propose that this work could lead to strategies to broaden and expand 
the functional CD8+ T cell repertoire within latently infected sensory ganglia, which may reduce 
the incidence of HSV-1 reactivation and recurrent disease.   
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8.0  FUTURE DIRECTIONS 
8.1 METHODS TO ENHANCE CD8+ T CELL LATENCY MONITORING 
 Given the recent insights into how phase 1 “animation” leads to phase 2 progression of 
full lytic reactivation events in sensory ganglia, it becomes possible to think about how CD8+ T 
cells could better monitor for and prevent reactivation. In the promoter virus studies discussed in 
Chapter 5, one obvious question was not addressed: Does earlier CD8+ T cell recognition of viral 
targets better prevent progression to late phase 2 and full reactivation? Because the mouse model 
is a good latency model, but not an ideal reactivation model, it is difficult to answer this question 
in vivo. While it is possible to force mice to reactivate through the use of histone modifying 
chemical treatment, stress, or UV-light, there are many difficulties working with these 
models[59]. 
 To further address this question, mice could be infected with the aforementioned 
constitutive, early, latently active, or late viral promoters driving the gB498-505 to establish latent 
TG infections. Using the ex vivo reactivation approach, wherein latently TG are dissociated and 
cultured, with endogenous CD8+ T cells depleted, and purified gB-CD8s added to the culture. 
Monitoring for reactivation events over time in the presence of gB-CD8s, should inform on the 
ability of CD8s to respond at late times in reactivation. As seen in Figure 9, gB-CD8s are not 
protective against the S1L virus, and require recognition of their cognate antigen to elicit effector 
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function. If gB-CD8s are deficient in responding to late genes, we would expect that they 
recognize late viral gene products, become activated, and initiate effector functions directed at 
TG neurons, yet the reactivation event may have progressed too far to stop by this time, and 
significant virus production would be detected in these cultures. Our hypothesis is that by the 
time γ2 viral gene products start to be expressed, HSV-1 α, β, and to some extent γ1, viral gene 
products will be expressed largely unchecked, leading to intracellular conditions that largely 
favor viral replication. Given the extensive immune evasion strategies employed by HSV-1, 
CD8+ T cell responses at this late time may be fighting an uphill battle, and fail to effectively 
control release of infectious virus. This model is not perfect however, as it bypasses the necessity 
of the virus to undergo axonal transport from the TG to the surface as is necessary in vivo, and it 
is largely unknown whether CD8+ T cells can block this vital transport step. Conversely, this 
same approach could be used to determine the effect that early and strong promoters have on 
CD8+ T cell blockage of reactivation. If our hypothesis is true, and late antigen recognition is 
inefficient at blocking reactivation events, it would be advantageous to design future therapy 
strategies at targeting early viral genes. 
 As an alternative strategy to expressing antigen earlier, it may be advantageous to have 
antigen that is expressed more frequently during latency. IFNγ has been shown to be effective at 
reducing viral phase 1 gene expression and invoking a “quieter” latent state in viral lytic 
genes[142]. Therefore, provoking more frequent CD8+ T cell responses directed at latently 
infected neurons may be highly advantageous to blocking progression to phase 2. To that end, 
we propose the use of chromatin insulating sequences, similar to those seen in the LAP virus 
presented in Chapter 5. By using better characterized and stronger chromatin insulating 
sequences, such as that identified in the β-globin locus in chickens[213], it may be possible to 
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enhance expression of peptide-expressing cassettes that will invoke CD8+ T cell responses more 
often. A possible negative consequence to this, however, is the increased likelihood of 
exhausting TG-resident CD8+ T cells, and a balance would need to be found. As intrinsic 
neuronal type 1 interferon responses also push the virus into quieter latency, it also may be 
possible to design recombinant HSV-1 that elicits stronger IFNα/β responses, which would 
bypass the need for constant CD8+ T cell activation. 
8.2 MECHANISM OF LATE GENE CD8+ T CELL PRIMING DEFECT 
Since a large number of HSV-1 encoded proteins are expressed as late genes, it would be 
useful to understand why they are disfavored as CD8+ T cell targets. In Chapter 5, we showed 
that of the three γ2 late gene promoters selected, gCp failed to prime gB-CD8 responses 
efficiently, and UL38p and UL41p failed to prime gB-CD8 responses at all. As these viruses all 
had similar expression cassettes, with the gB498-505 linked as a fusion to EGFP, the only variable 
is the amount and timing of antigen expression. This seemed to somewhat coincide with the later 
expression as determined by infected fibroblast cocultures. As discussed above, this defect in 
priming by late genes has been seen in other viral models. In vaccinia virus models of infection, 
viral genes expressed late are poor at priming CD8+ T cells, and are physically sequestered 
within infected cells, and so are inefficiently processed and cross-presented[188, 189]. Indeed, in 
HSV-1 infections of DCs, there is a late-infection block of DC activation and maturation[214]. 
Expression of the viral UL41 gene product, the tegument protein referred to as the virion-host 
shutoff (vhs) gene, has been demonstrated to block DC activation, and their ability to activate 
naïve CD8+ T cell populations[215, 216], with vhs-knockout viruses allowing DCs to retain 
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function [38]. Thus, it may be of future interest to determine whether vhs-knockout mutants 
could more efficiently prime CD8+ T cell responses against late viral gene products in our model, 
as this may be beneficial in the design of effective vaccine vectors. 
By use of a recombinant CRE-reporting mouse strain, such as the B6.Ai9(RCL-tdT), 
which express a bright fluorescent reporter (tdTomato) after CRE expression, it may also be 
possible to determine whether viral late genes are expressed in DCs within the context of early 
CD8+ T cell priming. By creating a recombinant HSV-1 expressing a CRE-gB498-505 fusion with a 
nuclear localization signal, under control of α, β, or γ2 promoters, we should be able to mark any 
cells that express (or take up) intact CRE-gB498-505, and thus mark most cells that are capable of 
presenting the gB498-505 epitope from the chosen promoter. Subsequent flow analysis on DLN of 
infected mice would determine the relative number of DC that take up viral antigen for 
processing, as well as characterize the subset of DC. If late genes are not expressed or processed 
in large numbers within the necessary DLN DC populations, this may explain the discrepancy 
between the amount of in vitro CD8+ T cell recognition and the CD8+ T cell priming defect 
observed in vivo. 
8.3 ALTERNATIVE VIRAL VECTOR STRATEGIES TO PRIME GANGLIONIC 
CD8+ T CELL RESPONSES 
In order to design better strategies for eliciting HSV-1 specific TG-CD8+ T cell responses 
prior to HSV-1 infection, we need to rethink the design of the vectors assessed in Chapter 6. 
AAV has rather limited coding capacity, but can accommodate several viral epitopes. The main 
issues with this vector are 1) the lack of neurotrophism in our model, and 2) the low 
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immunogenicity of AAV vectors. The first problem is a common one in the cornea, as we have 
subsequently engaged with several researchers (personal communication) unable to target 
corneal nerves with topically applied AAV vectors in mice. However, this issue can be overcome 
by using a skin model of HSV-1, where sensory termini present in the skin are known to be 
targeted by several AAV serotypes, and very similar CD8+ T cell dynamics are seen within the 
DRG[200-203]. The second issue is also readily overcome by ensuring the use of an 
immunogenic transgene (linked to HSV-1 CD8+ T cell epitopes) expressed from the AAV 
vector, which will elicit CD8+ T cell responses within local DLN [217]. Whether these CD8+ T 
cell responses are able to traffic to AAV transduced DRG neurons is not known and will need to 
be investigated.  
The use of PRV as a potential therapeutic is also still a potential avenue of research, with 
the pathogenicity observed in mouse corneas necessitating a further PRV attenuation. The major 
viral transactivator in PRV, and only immediate early gene expressed, IE180, an attractive target 
to knock out. This would mirror many potential HSV-1 recombinant vaccine vector strategies in 
which ICP4 has been deleted, which yields highly attenuated viruses that are able to persist in 
latently infected cells[218]. IE180 is a highly toxic gene in cell culture, and successful deletion 
knockouts grown in conditionally expressing complementing cell lines have only recently been 
described [217]. This choice of viral vector would have many benefits, including: 1) not 
expressing viral genes that are toxic within infected neurons, thus likely reducing the loss of 
corneal sensory nerves and the disease as detailed previously. 2) the lack of a strong viral 
transactivator would prevent large amounts of antigen from expressing during PRV latency 
within TG neurons, thus reducing the likelihood of exhausting antiviral TG-resident CD8+ T 
cells. 3) Using PRV that lacks IE180 would reduce the likelihood that PRV inoculation would 
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transactivate HSV-1 gene expression in latently coinfected neurons. 4) PRV has no overlap with 
HSV-1 CD8+ T cell epitopes, allowing us to methodically induce and study the efficacy of CD8+ 
T cells that target HSV-1 genes at specific points in the viral life cycle (α, β, γ) for their ability to 
prevent the establishment of viral latency. 
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